Selective decrotonylation inhibitors and methods of using the same

Selective histone decrotonylation inhibitors targeting HDAC3 outside the zinc-binding pocket enhance HIV transcription by increasing crotonylation, effectively disrupting HIV latency in CD4+ T cells and brain microglia, addressing the limitations of current LRAs.

WO2026241074A1PCT designated stage Publication Date: 2026-11-19THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027238
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-09-24
Filing Date
2026-05-08
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current latency reversal agents (LRAs) for HIV have not effectively reduced the stable, latently infected HIV reservoir, highlighting the complexity of epigenetic regulation and the need for novel approaches to target histone crotonylation pathways for HIV latency reversal.

Method used

Development of selective histone decrotonylation inhibitors (HDCRi) that target HDAC3, specifically binding outside the zinc-binding pocket to inhibit histone decrotonylation, thereby increasing histone crotonylation and activating HIV transcription in CD4+ T cells and brain microglia.

Benefits of technology

The HDCRi, such as citarinostat, effectively disrupts HIV latency in CD4+ T cells from HIV-positive individuals and brain microglia, delaying re-entry into latency and robustly activating HIV transcription with minimal impact on histone acetylation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000003_0002
    Figure IMGF000003_0002
  • Figure IMGF000003_0003
    Figure IMGF000003_0003
Patent Text Reader

Abstract

This disclosure is directed towards the identification of selective decrotonylation inhibitors and their use in methods for treating HIV latency.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Attorney Docket No. 393976-00119

[0002] SELECTIVE DECROTONYLATION INHIBITORS AND METHODS OF USING THE

[0003] SAME

[0004] FIELD OF THE INVENTION

[0005] This disclosure is directed towards the identification of selective decrotonylation inhibitors and their use in methods for treating HIV latency.

[0006] GOVERNMENT SUPPORT

[0007] This invention was made with government support under Grant No. R21AI167709, R01MH136852, and RO 1 Al 186609 awarded by the National Institutes of Health. The government has certain rights in the invention.

[0008] BACKGROUND

[0009] Globally, an estimated 40.8 million people lived with HIV in 2024, with 77% receiving antiretroviral therapy (ART). In the United States, over 1.2 million people live with HIV, with about 31,800 new infections in 2022. Modern treatments, such as ART, make HIV a manageable chronic condition, allowing people to live long, healthy lives. Treatment aims to achieve and maintain viral suppression, which prevents disease progression and transmission.

[0010] However, despite the remarkable success of antiretroviral therapy (ART) in suppressing active viral replication and transforming HIV-1 (HIV) into a manageable chronic condition, the stable, latently infected, replication-competent HIV reservoir remains a major barrier to HIV eradication1'3. These reservoirs evade the host immune system and are resistant to antiviral therapy for eradication. To address this challenge, latency reversal agents (LRAs) have been explored to reactivate viral gene expression in ART-suppressed people with HIV (PWH). This reactivation aims to render infected cells susceptible to viral cytopathic effects or immune-mediated clearance, potentially facilitating a cure for HIV4,5. Although LRAs have been shown to successfully stimulate viral gene expression in vitro and in vivo, they typically only reactivate a small subset of latent proviruses and have not led to significant reductions in reservoir size. As a result, the translation of this strategy into clinical practice remains elusive6'8.

[0011] Epigenetic regulation plays a critical role in maintaining HIV latency9, with mechanisms such as histone modifications, DNA methylation, and chromatin remodeling tightly controlling theAttorney Docket No. 393976-00119

[0012] transcriptional silencing of integrated HIV proviruses10. Among these mechanisms, histone deacetylases (HDACs) and histone methyltransferases (HMTs), rather than DNA methylation, appear to be critical regulators of HIV latency in primary CD4+T cells11. Inhibiting HDAC or HMT has shown potential for reactivating latent HIV, and several inhibitors targeting these enzymes have been explored as potential LRAs12'14. Unfortunately, clinical trials15,16have failed to achieve robust latency reversal, further demonstrating the complexity of epigenetic regulation.

[0013] 14.17

[0014] Furthermore, recent studies have revealed that the histone acetyltransferase (HAT) p300 also catalyzes histone crotonylation18'20, a modification that has been shown to stimulate gene transcription18,21. In parallel, HDACs also function as histone decrotonylases (HDCRs)2223, contributing to the regulation of histone crotonylation. While histone acetylation is widely studied and recognized for its role in transcription regulation, histone crotonylation has emerged as a potent mark for transcriptional activation, and HDACs play a critical role in removing crotonyl marks24. Recent findings suggest that p300-catalyzed histone crotonylation stimulates gene transcription more effectively than acetylation alone18,25'27, raising the possibility that targeting the crotonylation pathway could improve latency reversal efforts. However, the role of HDCR in HIV transcription and latency in human immune cells remains unclear, largely due to the overlapping acylation activities of the HDCR enzymes.

[0015] As such, there is a significant unmet medical need to develop suitable LRAs for treating HIV infection, particularly HIV latency.

[0016] SUMMARY

[0017] The disclosure is directed towards methods of

[0018] (a) reversing HIV latency in a subject diagnosed with an HIV infection, the method comprising administering a therapeutically effective amount of a compound of Formula (I); and / or

[0019] (b) inhibiting histone decrotonylation activity of a histone deacetylase 3 (HDAC3) enzyme by contacting a cell with a compound of Formula (I):

[0020] C-L-Z

[0021] Formula (I)

[0022] or any pharmaceutically acceptable salt and / or stereoisomer thereof, wherein:

[0023] Attorney Docket No. 393976-00119

[0024] Z is selected from the group consisting of

[0025]

[0026]

[0027] L is a linker selected from the group consisting of a bond, -CH2-(CH2)n-, -CH=CH-,

[0028]

[0029] compound is a histone decrotonylation (HDCR) inhibitor.

[0030] BRIEF DESCRIPTION OF THE DRAWINGS

[0031] FIG. 1A shows that crotonylation is associated with HIV transcription and latency reversal: a primary CD4+T cell model of latency was activated with anti-CD3 / CD28 dynabeads. The percentage of GFP+cells was measured by flow cytometry (top panel), representing HIV latencyAttorney Docket No. 393976-00119

[0032] reversal. The levels of the non-canonical (nc) NF-KB components pl 00 and p52, as well as ENL and CDYL were measured by western blot (bottom panel) (n = 3). The relative intensity was shown with results normalized to DMSO control.

[0033] FIG. IB shows that crotonylation is associated with HIV transcription and infection: Primary CD4+T cells from HIV-negative donors were infected with HIV-1 (SF162) and treated with or without 40 μM NaCr (n = 3). HIV transcription levels were measured by RT-qPCR targeting the HIV LTR, with results normalized to day 1 (left panel). The percentage of p24 positive cells was measured by HIV-Flow assay (right panel).

[0034] FIG. 1C shows that decrotonylation activity in HDAC3 is associated with the suppression of HIV transcription: TZM-bl luciferase reporter cells were transfected with empty vector (EV), Tat, wildtype (WT) HDAC3, or mutant HDAC3 (HDAC3-VRPP or HDAC3-Y298H), or Tat in combination with WT or mutant HDAC3 for 2 days (n = 3).

[0035] FIG. ID shows that crotonylation activity in p300 is associated with HIV transcription: A similar luciferase assay was performed with WT-p300 and mutant p300-I1395G. The level of Tat-induced HIV transcription was measured by luciferase assay, with results normalized to the EV control (n = 4). The p values were determined using two-way ANOVA with multiple comparisons (b, left panel), two-tailed unpaired Student’s t-test (b, right panel), or one-way ANOVA with multiple comparisons (c).

[0036] FIG. 2A shows that histone deacetylase inhibitors also inhibit histone decrotonylation but benzamide-containing HDACi MS-275 showed selectivity in inducing histone crotonylation but not acetylation: Representative western blotting of indicated histone marks in 2D 10 cells treated with NaCr 40 mM, SBHA 2.5 pm, SAHA 350 nM, M344 5 μm, MS-275 500 nM, Splitomicin 100 pm, and Apicidin 100 nM for 1 hour. The relative intensity was shown below with results normalized to the DMSO control.

[0037] FIG. 2B shows that benzamide-containing HDACi RGFP966 showed selectivity in inducing histone crotonylation but not acetylation: Representative western blotting of indicated histone marks in 2D10 cells treated with Mocetinostat (100 nM, 1 pM, 10 pM), RG2833 (100 nM, 1 pM, 10 pM), RGFP966 (1 pM, 5 pM, 10 pM), and BG45 (5 pM, 15 pM, 25 pM) for 2 hours.

[0038] FIG. 2C shows that benzamide-containing HDAC3i RGFP966 showed selectivity in inducing histone crotonylation but not acetylation: Representative western blotting of indicatedAttorney Docket No. 393976-00119

[0039] histone marks in primary CD4+T cell model of latency treated with same doses of Mocetinostat, RG2833, RGFP966, and BG45 for 4 hours.

[0040] FIG. 2D shows that benzamide-containing HDAC3i RGFP966 was potent in inducing HIV transcription from latency: 2D10 cells were treated with indicated HDACi for 24 hours. HIV transcription levels were measured by RT-qPCR targeting the HIV-1 long LTR, with results normalized to DMSO control (n = 5). DMSO was used as a negative control. Results are representative of 3 biological replicate experiments with consistent results. The P values were determined using one-way ANOVA with multiple comparisons.

[0041] FIG. 3A shows fluorine substitution on the benzamide ZBG of HDAC3i FGRP966 impacted HDCR activities in HIV latency models: 2D10 cells were treated with RGFP966 and mod-RGFP966 at the indicated concentrations for 24 hours. The expression of GFP was measured by flow cytometry (n = 3). Statistical analysis demonstrated significant differences between RGFP966 and mod-RGFP966.

[0042] FIG. 3B shows fluorine substitution on the benzamide ZBG of HDAC3i RGFP966 impacted HDCR activities in HIV latency models: Primary CD4+T cell model of latency was treated with NaCr 40 mM, SAHA 350 nM, RGFP966 10 pm, and mod-RGFP966 10 pm for 4 or 24 hours. HIV transcription levels were measured by RT-qPCR targeting the HIV-1 long LTR, with results normalized to DMSO control (n = 5).

[0043] FIG. 3C shows fluorine substitution on the benzamide ZBG of HDAC3i Mocedinostat impacted HDCR activities in HIV latency models: 2D10 cells were treated with RGFP966 and mod-RGFP966 for 4 hours. DMSO was used as a negative control. Histones were extracted for total histone 3 and PTMs analysis using western blot.

[0044] FIG. 3D shows adding fluorine on the benzamide ZBG of HDAC3i Mocedinostat exhibited significantly reduced potency in reversing HIV latency, except at the highest concentrations, compared to the parental mocetinostat in HIV latency models: 2D 10 cells were treated with mocetinostat and mod-mocetinostat at the indicated concentrations for 24 hours. The expression of GFP was measured by flow cytometry (n = 3). Statistical analysis demonstrated significant differences between mocetinostat and mod-mocetinostat.

[0045] FIG. 3E shows adding fluorine on the benzamide ZBG of HDAC3i Mocedinostat impacted HDCR activities in HIV latency models: 2D 10 cells were treated with mocetinostat and mod-Attorney Docket No. 393976-00119

[0046] mocetinostat for 4 hours. DMSO was used as a negative control. Histones were extracted for total histone 3 and PTMs analysis using western blot.

[0047] FIG. 3F shows fluorine substitution or adding on the benzamide ZBG of HDAC3i impacts HDCR activities in HIV latency models: Primary CD4+T cell model of latency was treated with the indicated HDACi for 24 hours, and the expression of GFP was measured by flow cytometry (n = 3). DMSO was used as a negative control. Results are representative of 3 biological replicate experiments with consistent results. The P values were determined using one-way ANOVA with multiple comparisons.

[0048] FIG. 4A shows that predicted HDAC3 structure is almost the same as the experimental structure of HDAC3 within the HDAC3 super complex: A modified version of the HDAC3 crystal structure (PDB: 4A69) with the DAD and IP4 removed compared with the AlphaFold 3 predicted HDAC3 crystal structure.

[0049] FIG. 4B shows that molecular docking of HDACi into the enzyme pocket of HDAC3: Docking of selected HDAC3i into the enzyme pocket of HDAC3, distinct from nonselective HDACi SAHA. Appling this docking profile identified Citarinostat as a potential selective HDCRi and Tucidinostat as potential selective HDACi.

[0050] FIG. 4C shows that Citarinostat was selective in HDCR but not HDAC: 2D10 cells and primary CD4+T cells were treated with the indicated HDACi for 0.5 hours. Total histone 3 and histone PTMs were detected by western blot.

[0051] FIG. 4D shows that selective HDCRi Citarinostat was potent in HIV latency reversal: 2D 10 cells were treated with citarinostat or tucidinostat for 24 hours and the expression of GFP cells was measured by flow cytometry (n = 5). The P values were determined using one-way ANOVA with multiple comparisons.

[0052] FIG. 4E shows that Citarinostat was selective in HDCR but not HDAC: Primary CD4+cells were treated with citarinostat or tucidinostat for 0.5 hours. Total histone 3 and histone PTMs were detected by western blot. The relative intensity was shown below with results normalized to DMSO control.

[0053] FIG. 4F shows that selective HDCRi had minimal activities in other histone arylations: CD4+cells were treated with RGFP966, mod-GRFP966, or citarinostat for 0.5 hours. Total histone 3 and histone PTMs were detected by western blot.

[0054] Attorney Docket No. 393976-00119

[0055] FTG. 5A shows that predicted amino acids surrounding the pocket sites are critical for HDCR activity within HDAC3 enzyme: Citarinostat, RGFP966, and mod-RGFP966 were docked against the enzyme pocket of HDAC3. Single-letter abbreviations for the amino acid residues are as follows: D, Asp; Q, Gin; and R, Arg.

[0056] FIG. 5B shows that amino acid mutations surrounding the pocket sites diminish HDCR activity within HDAC3 enzyme: Primary CD4+T cells were nucleofected with empty vector (EV) or HDAC3 WT / D57A / Q113A / R265A / R301A. After 5-7 days, total histone 3 and histone PTMs were detected by western blot. The relative intensity was shown below with results normalized to WT HDAC3.

[0057] FIG. 6A shows that selective HDCRi Citarinostat enhanced histone crotonylation at H3K27 or H3K18 with minimal impact on histone acetylation: 2D10 cells were treated with 0.5 pM modified RGFP966 and 5 pM citarinostat for 24 hours. Immunoprecipitation was performed using antibodies specific to H3K18Cr, H3K27Cr, and panKac. Precipitated DNA fragments were amplified using LTR- and NUCl-specific primers and detected by a SYBR green qPCR (n=6).

[0058] FIG. 6B shows that HDCR-targeted inhibition by RGFP966 delayed HIV entry into latency: Primary CD4+T cell model of latency was reactivated with anti-CD3 / CD28 dynabeads. After 2 days, activation beads were removed. Cells were further treated with modified RGFP966 1.5 pM on day 1 and day 2. Cells were collected and the expression of GFP cells was analyzed by flow cytometry at the indicated time points.

[0059] FIG. 6B shows that HDCR-targeted inhibition by Citarinostat delayed HIV entry into latency: Primary CD4+T cell model of latency was reactivated with anti-CD3 / CD28 dynabeads. After 2 days, activation beads were removed. Cells were further treated with citarinostat 1 pM at day 1, 2, 4, 6, and 8 (c) (n = 3). Cells were collected and the expression of GFP cells was analyzed by flow cytometry at the indicated time points.

[0060] FIG. 7A shows that selective HDCRi disrupted latent HIV in T cells isolated from PWH or NHPs on ART: Peripheral resting CD4+T cells were isolated from 8 people with HIV on ART and treated with the indicated compounds for 24 hours. The cell-associated HIV gag levels were measured by ddPCR, with results shown individually for each donor, including triplicate ddPCR data.

[0061] FIG. 7B shows that selective HDCRi disrupted latent HIV in T cells from PWH on ART: A combined summary of the ddPCR results from all donors (n = 8) are presented as averages.

[0062] Attorney Docket No. 393976-00119

[0063] FTG. 7C shows that selective HDCRi disrupted latent HIV in T cells isolated from PWH on ART: Cell-free HIV gag levels in the culture supernatant from 3 donors treated with SAHA and citarinostat were measured.

[0064] FIG. 7D shows that procedures to isolate brain microglia from PWH or NHPs on ART: Brain tissue from NHP or participants with HIV was mechanically dissociated to generate a singlecell suspension, followed by percoll gradient separation. CD3+T cells were depleted using a CD3 selection kit. Brain MG were then isolated from the CD3-negative fraction by CD1 lb+selection. Brain MG were cultured ex vivo for 1 -2 weeks to allow recovery and attachment before being used in the LRA study.

[0065] FIG. 7E shows that selective HDCRi disrupted latent HIV in the brain microglia isolated from PWH on ART: Brain MG from NHPs were treated with LRAs or DMSO control (n = 4). After 24 hours, the drugs were removed, and cells were cultured for another 6 days. Cells and culture supernatants were harvested for HIV RNA measurement by ddPCR.

[0066] FIG. 7F shows that selective HDCRi induced SIV transcription in the brain microglia isolated from NHPs on ART: Brain MG from NHPs were treated with LRAs or DMSO control (n = 6). After 24 hours, the drugs were removed, and cells were cultured for another 6 days. Cells and culture supernatants were harvested for SIV RNA measurement by ddPCR.

[0067] FIG. 8 shows two bar graphs showing selective HDCRi was potent in HIV latency reserval.

[0068] 2D10 cells were treated with indicated HDACi for 4 and 6 hours. HIV transcription levels were measured by RT-qPCR targeting the HIV-1 LTR, with results normalized to DMSO control (n = 5).

[0069] FIG. 9 shows two bar graphs of the cellular viability of CD4+T cells after treatment with selective HDCRi. The primary CD4+T cell model of latency was treated with the indicated selective HDCRi for 24 hours, and the percentage of live cells was measured by flow cytometry (n=3).

[0070] FIG. 10A shows the characterization of new selective HDCRi docking outside of the Zn2+ catalytic pocket: Prediction of some currently available HDACi docking into ALgenerated enzyme pocket of HDAC3.

[0071] FIG. 10B shows the characterization of new selective HDCRi in HIV latency reversal: 2D 10 cells were treated with indicated concentrations of HDACi for 0.5 hour and histone were extracted for western blot.

[0072] Attorney Docket No. 393976-00119

[0073] FTG. 10C shows that the selective HDCRi Citarinostat did not induce acetylation of Tublin protein: 2D10 cells were treated with indicated concentrations of citarinostat for 1 hour. Hyperacetylation of a-tubulin was measured by western blot.

[0074] FIG. 10D shows the characterization of HDACi in HIV latency reversal: 2D10 cells were treated with indicated concentrations of HDACi for 24 hours and the level of GFP+ cells were measured by flow cytometry (n=3).

[0075] FIG. 10E shows that the selective HDCRi had minimal activities in inducing other acylations: 2D10 cells were treated with indicated concentrations of HDCRi for 0.5 hour and histone were extracted for western blot.

[0076] FIG. 11A shows the virtual screening of selective HDCRi in FDA-approved drugs: Lonafamib, Olaparib, and Deferasirox were docked against the Al-generated enzyme pocket of HDAC3.

[0077] FIG. 11B shows HIV latency reversal by virtual screened FDA-approved drugs with HDCRi activity: 2D10 cells were treated with Lonafarnib, Olaparib, and Deferasirox at the indicated concentrations for 24 hours. The level of GFP expression was measured by flow cytometry (n=6).

[0078] FIG. 11C shows the virtual screening of selective HDCRi in the induction of histone crotonylation and acetylation: Primary CD4+ T cells were treated with Lonafarnib, Olaparib, and Deferasirox for 1 hour. Total histone 3 and histone PTMs were detected by western blot.

[0079] FIG. 12A shows that selective HDCRi potently disrupted latent HIV in resting CD4+T cells isolated from PWH on suppressive ART: Peripheral resting CD4+T cells isolated from PWH were treated with the indicated compounds and the cell-associated HIV long LTR was measured by RT-ddPCR.

[0080] FIG. 12B shows that selective HDCRi potently disrupted latent HIV in resting CD4+T cells isolated from PWH on suppressive ART: Peripheral resting CD4+T cells isolated from people with HIV were treated with the indicated compounds and the long HIV LTR was measured by RT-ddPCR.

[0081] FIG. 13 shows that selective HDCRi induced SIV in brain microglia isolated from NHPs. Brain MG from NHPs were treated with citarinostat 5 pM or DMSO control. After 24 hours, the drugs were removed, and cells were cultured for another 6 days. Cells and culture supernatants were harvested for cell-free SIV RNA measurement by RT-ddPCR.

[0082] Attorney Docket No. 393976-00119

[0083] FTG. 14 shows Fluorine substitution on the benzamide ZBG of HDAC3i impacts HDCR activities in HIV latency models. 2D 10 cells were treated with mocetinostat and mod-mocetinostat for 4 hours. DMSO was used as a negative control. Histones were extracted for total histone 3 and PTMs analysis using Western blot.

[0084] FIG. 15A shows Structural and functional characterization of HDAC3i reveals mechanisms of histone decrotonylation modulation. Primary CD4+T cells were treated with the indicated HDACi for 0.5 hours. Total histone 3 and histone PTMs were detected by Western blot. The relative intensity was shown below with results normalized to the DMSO control. 0.3 mg / mL HDAC3 / NCOR1 were incubated with acetylated histone 3.

[0085] FIG. 15B shows Structural and functional characterization of HDAC3i reveals mechanisms of histone decrotonylation modulation. Primary CD4+T cells were treated with the indicated HDACi for 0.5 hours. Total histone 3 and histone PTMs were detected by Western blot. The relative intensity was shown below with results normalized to the DMSO control. 0.3 mg / mL HDAC3 / NCOR1 were incubated with crotonylated histone 3 or acetylated histone 3 in the presence or absence of different concentrations of citarinostat. Total histone 3 and histone PTMs were detected by western blot. For some, DMSO was used as a negative control. Results are representative of 3 biological replicate experiments with consistent results.

[0086] FIG. 16A shows Citarinostat binds a conserved external site on HDAC3 and HDAC8 to selectively inhibit decrotonylase activity. Structural overlay of HDACI, HDAC2, HDAC3, and HDAC8 bound to SAHA with 0.05 mg / mL HDAC2.

[0087] FIG. 16B shows Citarinostat binds a conserved external site on HDAC3 and HD AC 8 to selectively inhibit decrotonylase activity. Structural overlay of HDACI, HDAC2, HDAC3, and HDAC8 bound to Citarinostat with 0.05 mg / mL HDAC2.

[0088] FIG. 16C shows Citarinostat binds a conserved external site on HDAC3 and HDAC8 to selectively inhibit decrotonylase activity. Structural overlay of HDACI, HDAC2, HDAC3, and HDAC8 bound to Citarinostat or SAHA with 0.4 mg / mL HDAC8.

[0089] FIG. 16D shows that Citarinostat binds a conserved external site on HDAC3 and HDAC8 to selectively inhibit decrotonylase activity, which were incubated with crotonylated histone 3 or acetylated histone 3 in the presence or absence of different concentrations of citarinostat. Total histone 3 and histone PTMs were detected by Western blot.

[0090] Attorney Docket No. 393976-00119

[0091] FTG. 16E shows that Citarinostat binds a conserved external site on HDAC3 and HDAC8 to selectively inhibit decrotonylase activity. HDAC3 was knocked out in 2D 10 cells via CRISPR-Cas9, using a non-targeting gRNA as the control, and the cells were cultured for five days.

[0092] FIG. 16F shows Citarinostat binds a conserved external site on HDAC3 and HDAC8 to selectively inhibit decrotonylase activity. In a separate experiment, 2D10 cells were pretreated for 24 h with DMSO or 20 nM YX968, an HDAC3 / 8 dual PROTAC. For both experimental series, cells were subsequently treated for 30 min with the following HDACi: DMSO (vehicle), 350 nM SAHA, 0.1 μM citarinostat, 5 pM RGFP966, or 5 pM mod-RGFP966. Histones were then extracted and analyzed by Western blot with antibodies for specific PTMs or total histone H3.

[0093] FIG. 17 shows that Selective HDCRi disrupts latent HIV in T cells and non-T cells isolated from PWH or NHPs on ART, wherein In a separate experiment, cells were treated with DMSO or 5 pM citarinostat (n = 5).

[0094] DETAILED DESCRIPTION

[0095] The presently disclosed subject matter will now be described more fully hereinafter. However, many modifications and other embodiments of the presently disclosed subject matter set forth herein will come to mind to one skilled in the art to which the presently disclosed subject matter pertains, having the benefit of the teachings presented in the foregoing descriptions. Therefore, it is to be understood that the presently disclosed subject matter is not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. In other words, the subject matter described herein covers all alternatives, modifications, and equivalents. In the event that one or more of the incorporated literature, patents, and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in this field. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.

[0096] The role of epigenetic regulation in HIV transcription and latency remains incompletely understood. In this study disclosed herein, the inventors demonstrate that HDAC3, despite lackingAttorney Docket No. 393976-00119

[0097] histone deacetylase (HDAC) activity, can inhibit Tat-mediated HIV transactivation through its parallel histone decrotonylation (HDCR) activity. Using chemical biology approaches, selective histone decrotonylase inhibitors (HDCRi) were identified that reverse HIV latency independently of HDAC or other histone acylation activities. Notably, the removal of fluorine from the benzamide ring enhances the HDCRi activity of HDAC3. Unlike dual -targeting HDAC inhibitors that target the Zn2+active site, molecular docking reveals that HDCRi bind outside the zinc-binding pocket. The selective HDCRi citarinostat significantly increases histone crotonylation at the HIV long terminal repeat with minimal effects on histone acetylation, triggering robust HIV transcription in Jurkat latency models, primary CD4+T cells isolated from individuals suppressed on antiretroviral therapy, as well as brain microglia isolated from both non-human primates and participants enrolled in the Last Gift rapid research autopsy cohort. In a model system, HDCRi also delays HIV re-entry into latency. Key residues (R265, R301, Q113, D57) are essential for HDCR selectivity. Mutation of these residues abolishes HDCR activity and increases histone crotonylation in CD4+T cells minimally affecting other acylation marks. Lastly, Citarinostat increases histone crotonylation at the HIV LTR, robustly activating HIV transcription in cell lines, primary CD4+T cells, and brain microglia from SIV-infected nonhuman primates and from participants in the Last Gift cohort following rapid research autopsy, highlighting HDCR’s involvement in HIV latency Together, these findings suggest that histone decrotonylation plays a unique role in HIV latency and might be targeted as a novel and promising strategy for disrupting HIV latency and advancing HIV cure efforts. As such, the disclosed histone decrotonylation ligands are described in more detail below.

[0098] I. Definitions

[0099] As used herein, the term “subject” or “patient” broadly refers to any animal, including but not limited to, human and non-human animals (e.g., dogs, cats, cows, horses, sheep, poultry, fish, crustaceans, etc.). As used herein, the term “patient” typically refers to a subject that is being treated for a disease or condition.

[0100] As used herein, the term “effective amount” refers to the amount of a composition sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, alone or in combination, applications or dosages and is not intended to be limited to a particular formulation or administration route.

[0101] Attorney Docket No. 393976-00119

[0102] As used herein, the terms “administration” and “administering” refer to the act of giving a drug, prodrug, or other agent, or therapeutic treatment to a subject or in vivo, in vitro, or ex vivo cells, tissues, and organs. Exemplary routes of administration to the human body can be through space under the arachnoid membrane of the brain or spinal cord (intrathecal), the eyes (ophthalmic), mouth (oral), skin (topical or transdermal), nose (nasal), lungs (inhalant), oral mucosa (buccal), ear, rectal, vaginal, by injection (e.g., intravenously, subcutaneously, intratumorally, intraperitoneally, etc.) and the like.

[0103] As used herein, the terms “co-administration” and “co-administering” refer to the administration of at least two agents (e.g., HDCR inhibitor and one or more additional therapeutics) or therapies to a subject. In some embodiments, the co-administration of two or more agents or therapies is concurrent. In other embodiments, a first agent / therapy is administered prior to a second agent / therapy. Those of skill in the art understand that the formulations and / or routes of administration of the various agents or therapies used may vary. The appropriate dosage for co-administration can be readily determined by one skilled in the art. In some embodiments, when agents or therapies are co-administered, the respective agents or therapies are administered at lower dosages than appropriate for their administration alone. Thus, co-administration is especially desirable in embodiments where the co-administration of the agents or therapies lowers the requisite dosage of a potentially harmful (e.g., toxic) agent(s), and / or when co-administration of two or more agents results in sensitization of a subject to beneficial effects of one of the agents via co-administration of the other agent.

[0104] As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vitro, in vivo or ex vivo.

[0105] The terms “pharmaceutically acceptable” or “pharmacologically acceptable,” as used herein, refer to compositions that do not substantially produce adverse reactions, e.g., toxic, allergic, or immunological reactions, when administered to a subject.

[0106] As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers including, but not limited to, phosphate buffered saline solution, water, emulsions (e.g., such as an oil / water or water / oil emulsions), and various types of wetting agents, any and all solvents, dispersion media, coatings, sodium lauryl sulfate, isotonic and absorption delaying agents, disintigrants (e.g., potato starch or sodium starch glycolate), and the like. TheAttorney Docket No. 393976-00119

[0107] compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see, e.g., Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, Pa. (1975), incorporated herein by reference in its entirety.

[0108] As used herein, the term “pharmaceutically acceptable salt” refers to any pharmaceutically acceptable salt (e.g., acid or base) of a compound of the present invention, which, upon administration to a subject, is capable of providing a compound of this invention or an active metabolite or residue thereof. As is known to those of skill in the art, “salts” of the compounds of the present invention may be derived from inorganic or organic acids and bases. Examples of acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

[0109] As used herein, the term “inhibit”, "inhibition" or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.

[0110] As used herein, the term “treat”, “treating" or "treatment" of any disease or disorder refers to alleviating or ameliorating the disease or disorder (i.e., slowing or arresting the development of the disease or at least one of the clinical symptoms thereof); or alleviating or ameliorating at least one physical parameter or biomarker associated with the disease or disorder, including those which may not be discernible to the patient.

[0111] As used herein, the term “prevent”, “preventing" or “prevention” of any disease or disorder refers to the prophylactic treatment of the disease or disorder; or delaying the onset or progression of the disease or disorder.

[0112] As used herein, the term a therapeutically effective amount" of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc.

[0113] Attorney Docket No. 393976-00119

[0114] As used herein, the term “anticancer agent” or anti neoplastic agent, refers to a therapeutic agent that is useful for treating or controlling the growth of cancerous cells.

[0115] As used herein, the term anti-HIC agent refers to a therapeutic agent that is useful for treating or controlling HIV infection and / or AIDS.

[0116] II Compounds

[0117] Provided herein are histone decrotonylation (HDCR) inhibitors for the treatment of disease, such as HIV, AIDS, and / or cancers and other diseases dependent on crotonylation and decrotonylation activities. In some embodiments, the compounds disclosed herein are selective histone decrotonylation (HDCR) inhibitors. In some embodiments, the compounds disclosed herein are compounds that exhibit histone decrotonylation (HDCR) inhibitory activity but not significant histone deacetylase (HD AC) inhibitory activity. In some embodiments, the compounds disclosed herein bind to the histone deacetylase 3 enzyme (HDAC3). In some embodiments, the compounds disclosed herein do not bind in the active site of the enzyme. In some embodiments, the compounds disclosed herein bind outside of the active site of the enzyme, i.e., adjacent to the active site. In some embodiments, the compounds disclosed herein bind to at least one of the following amino acid residues located outside of the active site of the enzyme: D57, Q113, R265 and / or R301.

[0118] In some embodiments, the compounds disclosed herein comprises a moiety (Z), a cap region (C) and a linker (L). In some embodiments, the compound disclosed herein is a compound of Formula (I):

[0119] C-L-Z

[0120] Formula (I)

[0121] or any pharmaceutically acceptable salt and / or stereoisomer thereof, wherein:

[0122] Z is selected from the group consisting of

[0123]

[0124]

[0125] Attorney Docket No. 393976-00119

[0126] L is a linker selected from the group consisting of a bond, -CH2-(CH2)n-, -CH=CH-,

[0127]

[0128] In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3.

[0129] In some embodiments, Z is selected from the group consisting

[0130]

[0131]

[0132] Attorney Docket No. 393976-00119

[0133]

[0134] In some embodiments, Z is O. In some embodiments, Z is O and L is-

[0135] 'OH

[0136] CH2-(CH2)n-, wherein n is 5. In some embodiments, Z is O, L is-CH2-(CH2)s-, and C is

[0137]

[0138]

[0139] , selected from a group

[0140] consisting of a bond, -CH2-(CH2)4-, -CH=CH-, and

[0141]

[0142] In some embodiments, Z

[0143] selected from a group consisting of a bond, -CH2-(CH2)4-, -CH=CH- and

[0144]

[0145] nd C is selected from the group consisting of

[0146]

[0147]

[0148] Attorney Docket No. 393976-00119

[0149] embodiments,

[0150]

[0151] bond and C is

[0152]

[0153] In some embodiments, Z is

[0154]

[0155] In some embodiments, Z is

[0156]

[0157] In some embodiments, Z is

[0158]

[0159] Attorney Docket No. 393976-00119

[0160]

[0161] In some embodiments, Z is selected from the group consisting

[0162]

[0163]

[0164] from the group consisting of a -CH2-(CH2)n-, -CH=CH-,

[0165]

[0166] and

[0167]

[0168] , wherein n is an integer selected from 1-6; C is selected from the groupAttorney Docket No. 393976-00119

[0169]

[0170] In some embodiments, Z is selected from the group consisting

[0171]

[0172] and L is selected from the group consisting of -CH=CH- and

[0173]

[0174] In some embodiments, Z is selected from the group consisting of

[0175]

[0176] selected from the group consisting of -CH=CH- and and C is selected from the group consisting

[0177]

[0178] and

[0179]

[0180] In some embodiments,

[0181]

[0182] Attorney Docket No. 393976-00119

[0183]

[0184] In some embodiments, the compound of Formula (I) has one or more of the following provisos:

[0185]

[0186] In some embodiments, Z is selected from the group consisting

[0187]

[0188]

[0189] ,,, g

[0190] Attorney Docket No. 393976-00119

[0191] selected from the group consisting

[0192]

[0193] In some embodiments, Z is

[0194]

[0195] . In some embodiments, Z is

[0196]

[0197] In some embodiments, Z is O and L is -CH2-(CH2)s-. In some embodiments, Z is

[0198]

[0199] Attorney Docket No. 393976-00119

[0200] In some embodiments, Z is

[0201]

[0202] In some embodiments, Z is

[0203]

[0204]

[0205] In some embodiments, Z is selected from the group consisting

[0206]

[0207]

[0208] , and C is selected

[0209]

[0210] .,.

[0211] Attorney Docket No. 393976-00119

[0212]

[0213] Exemplary compounds of Formula (I) include, but are not limited to,

[0214] 1.

[0215]

[0216] Attorney Docket No. 393976-00119

[0217]

[0218] The compounds described herein may in some cases exist as diastereomers, enantiomers, or other stereoisomeric forms. The compounds presented herein include all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof. Separation of stereoisomers may be performed by chromatography and / or recrystallization or by the forming diastereomers and separation thereof (Jean Jacques, Andre Collet, Samuel H. Wilen, “Enantiomers, Racemates and Resolutions”, John Wiley And Sons, Inc., 1981). Stereoisomers may also be obtained by stereoselective synthesis using synthetic methods known in the art. In some embodiments, the compounds disclosed herein are enantiomers having an enantiomeric excess (% ee) of at least about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 98%, or about 99.5%. In some embodiments, the compounds disclosed herein are disateremores havingAttorney Docket No. 393976-00119

[0219] a diatereomeric excess (% de) of at least about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 98%, or about 99.5%. In some embodiments, the compounds disclosed herein are present as enantiomeric or diastereomeric mixtures.

[0220] The methods and compositions described herein include the use of amorphous forms as well as crystalline forms (also known as polymorphs). The compounds described herein may be in the form of pharmaceutically acceptable salts. Active metabolites of these compounds having the same type of activity are included in the scope of the present disclosure.

[0221] In some embodiments, the compounds described herein may be formed as, and / or used as, pharmaceutically acceptable salts. The type of pharmaceutical acceptable salts, include, but are not limited to: (1) acid addition salts, formed by reacting the free base form of the compound with a pharm ceutically acceptable: inorganic acid, such as, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, metaphosphoric acid, and the like; or with an organic acid, such as, for example, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, trifluoroacetic acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedi sulfonic acid, 2-hydroxy ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene-l-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-l -carboxylic acid), 3-pheny 1 propionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, butyric acid, phenylacetic acid, phenylbutyric acid, valproic acid, and the like; (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e g., an alkali metal ion (e.g. lithium, sodium, potassium), an alkaline earth ion (e.g. magnesium, or calcium), or an aluminum ion. In some cases, compounds described herein may coordinate with an organic base, such as, but not limited to, ethanolamine, diethanolamine, triethanolamine, tromethamine, N- jnethylglucamine, dicyclohexylamine, tris(hydroxymethyl)methylamine. In other cases, compounds described herein may form salts with amino acids such as, but not limited to, arginine, lysine, and the like Acceptable inorganic bases used to form salts with compounds that include an acidic proton, include, but are not limited to, aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.

[0222] Attorney Docket No. 393976-00119

[0223] In some embodiments, the compounds and salts described herein include isotopically-labeled compounds. In general, isotopically-labeled compounds are identical to those recited in the various formulae and structures presented herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number most common in nature. Examples of isotopes that can be incorporated into the present compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine and chlorine, for example, 2H, 3H, 13C, 14C, 15N, 180, 170, 35S, 18F, 36C1, respectively. Certain isotopically-labeled compounds described herein, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and / or substrate tissue distribution assays. Further, substitution with isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, such as, for example, increased in vivo half-life or reduced dosage requirements.

[0224] In some embodiments, the compounds or salts described herein is a prodrug. In some embodiments, the compounds described herein may be formed as, and / or used as, prodrugs. A “prodrug” refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. Examples, without limitation, of a prodrug would be a compound described herein, which is administered as an ester or an amide (the “prodrug”) to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid and / or amine, the active entity, once inside the cell where water-solubility is beneficial. A further example of a prodrug might be a short peptide (polyaminoacid) or amino acid (natural or unnatural) bonded to an acid group or an amine group where the peptide or amino acid is metabolized to reveal the active moiety. In certain embodiments, upon in vivo administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically active form of the compound. In certain embodiments, a prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharmaceutically or therapeutically active form of the compound.

[0225] To produce a prodrug, a pharmaceutically active compound is modified such that the active compound will be regenerated upon in vivo administration. The prodrug can be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, toAttorney Docket No. 393976-00119

[0226] improve the flavor of a drug or to alter other characteristics or properties of a drug. In some embodiments, by virtue of knowledge of pharmacodynamic processes and drug metabolism in vivo, once a pharmaceutically active compound is determined, prodrugs of the compound are designed, (see, for example, Nogrady (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392; Silverman (1992), The Organic Chemistry of Drug Design and Drug Action, Academic Press, Inc., San Diego, pages 352-401, Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985; Rooseboom et al., Pharmacological Reviews, 56:53-102, 2004; Miller et al., J. Med. Chem. Vol. 46, no. 24, 5Q91-5116, 2003; Aesop Cho, “Recent Advances in Oral Prodrug Discovery”, Annual Reports in Medicinal Chemistry, Vol. 41, 395-407, 2006).

[0227] In some embodiments, the compounds disclosed herein bind to the histone deacetylase 3 (HDAC3) enzyme. In some embodiments, the compounds disclosed herein are allosteric inhibitors of the HD AC enzyme, meaning that the compounds bind at the HD AC enzyme at a site that is not the active site causing a change in the enzyme’s shape and function. This change reduces the enzymes ability to catalyze its reaction, i.e., decrotonylation activity, thereby inhibiting the enzyme’s activity.

[0228] III. Additional Studies

[0229] The following studies were carried out to further describe the utility of the compounds disclosed herein:

[0230] A. Crotonylation is associated with HIV transcription and latency reversal

[0231] Building on prior work33, the inventors investigated crotonylation signaling in HIV transcription using a primary CD4+T cell model of latency3132, where GFP serves as a transcriptional reporter for HIV. Following treatment with anti-CD3 / CD28 dynabeads, GFP+cells at day 2 gradually declined as HIV re-entered latency. As cleavage of pl 00 into p52 activates non-canonical NF-kB (ncNF-kB) signaling, important in driving HIV transcription32, ncNF-kB activation as a surrogate for HIV transcription was monitored. Consistent with GFP dynamics, ncNF-KB activation (via plOO cleavage) also peaked at day 2 and subsequently declined. Intriguingly, the temporal expression of ENL, a crotonylation reader and YEATS domain protein38, mirrored HIV transcription kinetics. Conversely, levels of the crotonylation-erasingAttorney Docket No. 393976-00119

[0232] enzyme CDYL decreased by 30-40% within 2-4 days post-activation but rebounded by day 7, coinciding with HIV latency re-establishment (FIG. 1A). These findings highlight the association between crotonylation signaling and HIV transcription regulation, aligning with the inventors’ earlier studies24.

[0233] Previous work by the inventors demonstrated that the supplementation of NaCr transiently elevates cellular crotonyl-CoA levels, inducing histone crotonylation and reactivating latent HIV in T cells2432. Extending this to HIV-infected primary T cells, one observed a 2- to 3-fold increase in HIV LTR-driven transcription after 6-8 days of NaCr treatment compared to untreated controls (FIG. IB, left panel) Moreover, HIV p24 flow cytometry demonstrated a significant increase in the frequency of p24+cells in the NaCr-treated group compared to untreated controls at day 8 (FIG. IB, right panel). Previous studies have reported HDAC3 mutants, such as VRPP and Y298H, possess decrotonylation activity but lack deacetylation activity22,39. The inventors found that like WT HDAC3, these HD AC activity-defective HDAC3 mutants were sufficient to suppress Tat-driven HIV transcription (FIG.1C). On the other hand, the inventors generated a p30011395G mutant, which has been shown to retain histone crotonyltransferase (HCT) activity but has impaired histone aceyltransferase (HAT) activity.40Interestingly, the I1395G mutant enhanced Tat-driven transactivation to a similar extent as wild-type (WT) p300 (FIG. ID), indicating that Tat transactivation of HIV is stimulated by HCT without HAT activity.

[0234] Taken together, these results suggest that crotonylation is likely to play a critical role in HIV transcription, and in parallel HDCR is involved in HIV latency. However, because the HDAC3 mutants retain residual (de)acylation activity toward other modifications (e.g., butyrylation, propionylation, and L-lactylation), the specific role of HDCR in HIV transcription and latency requires further definition.

[0235] B. Many histone deacetylase inhibitors also act as histone decrotonylase inhibitors

[0236] Emerging evidence has shown that some HDACi could have HDCRi activity in cancer cell studies41. The inventors hypothesized that certain currently available HDACi may exhibit selective activity towards HDCR over HDAC. A typical HDACi consists of three components: a zinc-binding group (ZBG), a cap region, and a linker that connects these two parts42. Although both the cap and linker are involved in the activities of HDACi, the ZBG plays a unique role in targeting the active site of HDAC activity in the enzyme, thus determining the potency and selectivity ofAttorney Docket No. 393976-00119

[0237] the HDACi43. Thus, for initial screening, several HDACi with diverse ZBG were selected, including vorinostat (SAHA), SBHA, M344, MS275, and Apicidin14,44’46, some of which have activity in HIV latency reversal14,46,47. The crotonylation inducer NaCr was also included. As a comparator, splitomicin48, an HDACi lacking the ZBG shown below, was included.

[0238]

[0239] In comparison, the crotonylation inducer NaCr and the well-characterized Class I HDACi SAHA, were included14,24. It was found that most of these compounds, including NaCr and SAHA, induced both histone crotonylation and acetylation, even within a few hours of stimulation.

[0240] Therefore, these compounds are referred to as dual-targeting inhibitors thereafter. However, MS-275 and splitomicin demonstrated notable selectivity by significantly enhancing histone crotonylation while causing minimal alterations in acetylation (FIG. 2A). Strikingly, MS-275 induced a higher increase in crotonylation levels (2.8-fold relative to DMSO control) compared to splitomicin (2.2-fold relative to DMSO control).

[0241] It was noticed that MS275 is HD AC3 -selective and contains a unique benzamide ZBG. Based on these findings, this analysis was expanded to other HDAC3 inhibitors (HDAC3i) that contain unique benzamide ZBG as shown below:

[0242] Attorney Docket No. 393976-00119

[0243]

[0244] BG4S

[0245] The inventor’s results indicated that overall HDAC3i with benzamide ZBGs, such as RG283349, RGFP96650, and BG4551, preferentially enhanced histone crotonylation over acetylation in both 2D10 cells (FIG. 2B) and primary CD4+T cell model of latency (FIG. 2C).

[0246] However, a high concentration of mocetinostat46induced high levels of acetylation. Of note, among these HDAC3i, RGFP966, a well-characterized specific HDAC3i, demonstrated a dosedependent increase in crotonylation with minimal effects on acetylation. These results suggest that RGFP966 may selectively inhibit histone decrotonylase activity. To assess the impact of these HDACi on HIV transcription, HIV transcription was measured by RT-qPCR at 4-, 6-, and 24 hours post-treatment. While minimal changes in transcription were observed in RGFP966-treated cells at 4 hours, a moderate increase of latency reversal was observed at 6 hours (FIG. 8). At 24-hour post-treatment, RGFP966 induced a significant latency reversal, achieving a five-fold increase compared to SAHA (FIG.2D). Given that SAHA inhibits both deacetylation and decrotonylation, and RGFP966 appears to act as a selective HDCRi, these findings suggest that benzamide ZBG containing HDCR3i may possess unique activities to selectively target HDCR over HDAC, yielding greater efficacy and the potential for fewer off-target or toxicity effects while reversing HIV latency.

[0247] Attorney Docket No. 393976-00119

[0248] C. Fluorine substitution on the benzamide ZBG of HDAC3i impacts HDCRi activities in reversing HIV latency

[0249] Not to be bound by any theory, but it is believed that the benzamide ZBG of HDAC3i determines the selectivity for HDCR over HDAC activity. To further investigate the structural basis of this selectivity, a unique fluorine modification on the benzamide ZBG ring of RGFP966 was studied. Given fluorine’s established role in modulating molecular stability, binding affinity, and reactivity52,53, it was hypothesized that fluorine may play some role in the HDCR selectivity and latency-reversing activity. It was speculated that removing fluorine might diminish the HDCR selectivity and activity of RGFP966. To test this, fluorine was removed from its benzamide ZBG to synthesize a modified RGFP966 (mod-RGFP966), as shown below:

[0250]

[0251] Contrary to our hypothesis, the mod-RGFP966 exhibited enhanced potency in reversing HIV latency at concentrations below 2 pM (FIG. 3A), alongside reduced cytotoxicity compared to the parent compound (FIG. 8). Both RGFP966 and mod-RGFP966 induced HIV expression in primary CD4+T cell latency model at 4- and 24-hour time points, with mod-RGFP966 showing superior efficacy (FIG. 3B). To examine whether this altered activity is due to HDCR inhibition, the inventors analyzed histone modification in HIV latency model 2D 10 and found that the mod-RGFP966 exhibited stronger activity in enhancing crotonylation with minimal impact on acetylation compared to the parental RGFP966 (FIG. 3C).

[0252] To further dissect fluorine’s role in HDCR activity, one leveraged mocetinostat46— a less selective HDACi lacking fluorine on its benzamide ZBG (FIG. 2B-C) — and synthesized a fluorine-modified analog (mod-mocetinostat) by introducing fluorine into this structural motif, see below:

[0253] Attorney Docket No. 393976-00119

[0254]

[0255] Interestingly, mod-mocetinostat exhibited reduced potency compared to mocetinostat in reversing HIV latency at lower concentrations (0.5-2 pM) but surpassed the parent compound's activity at higher concentrations (5 and 10 pM) (Fig. 3A), with no associated cytotoxicity. These observations indicate that some other pathways of HIV latency reversal related to mocetinostat / mod-mocetinostat are involved in HIV latency reversal, possibly due to its dual activity to both HDCR and HD AC. Histone modification analysis in 2D10 cells revealed that mod-mocetinostat induced both crotonylation and acetylation, mirroring the parental compound, although levels were lower than those observed with unmodified mocetinostat when administered at 5 and 10 pM (Fig. 14). The inventors extended their analysis to a primary CD4+T cell model of HIV latency. Consistent with earlier results, mod-RGFP966 exhibited significantly enhanced latency -reversing potency compared to the parent RGFP966 at all tested doses. Conversely, mod-mocetinostat showed a trend to reduce latency reversal, where at 1 pM it markedly reduced efficacy relative to its unmodified counterpart (Fig.3F). Together, these chemical biology studies suggest that fluorine on the benzamide ZBG does not significantly influence HDCR selectivity. Furthermore, its removal in RGFP966 unexpectedly enhances its activity towards inhibiting HDCR and significantly improves its latency-reversing potency.

[0256] D. Understanding the structural basis of selective HDCR by molecular docking of HDACi against the catalytic pockets of the HDAC3 structure

[0257] The results disclosed herein suggest HDCRi activity is due to neither the unique benzamide ZBG nor fluorine substitution. To uncover the underlying mechanism, interaction of HDCRi with HDAC3 were explored through molecular docking studies. Unfortunately, almost all the available HDAC3 crystal structures are within an HDAC3 super complex. For example, HDAC3 in complex with the DAD of its corepressor complex revealed an IP4 molecule at the protein-protein

[0258] Attorney Docket No. 393976-00119

[0259] interface54. In order to see if the removal of these proteins would have a potential effect on the structure of HDAC3 alone, AlphaFold (AF) was utilized to predict the HDAC3 structure. This structure exhibited a Root Mean Square Deviation (RMSD) of 0.68 A (overall) and a trimmed RMSD of 0.572 A, closely resembling the experimental HDAC3 structure within the super complex (FIG. 4A). For this reason, a modified version of the crystal structure (PDB: 4A69) was used with the DAD and IP4 removed and performed docking studies to predict the potential poses of dual-targeting and selective HDACi (FIG. 4B, FIG. 10a). SAHA, which can act as an HDACi and an HDCRi, was observed to dock deep within the ZBG pocket of HDAC3, a pattern also shared by many dual-targeting HDACi tested. Unexpectedly and in contrast to SAHA, RGFP966 and mod-RGFP966, both identified as selective HDCRi, docked just outside the catalytic pocket. This observation was intriguing, as it suggested that differences in docking patterns could play a critical role in determining the selectivity between deacetylase and decrotonylase activities with HDAC3 protein (FIG. 4B).

[0260] To test this hypothesis and to explore this further, additional HDACi were screened to analyze their docking profiles with HDAC3 (FIG. 4B, Fig. 10a). While most compounds docked deep within the catalytic pocket, one compound, citarinostat, docked just outside the pocket, similar to the previously identified selective HDCRi RGFP966 or mod-RGFP966. Based on this observation, we hypothesized that citarinostat should also exhibit HDCR selectivity over HD AC activity. When tested in HIV latency models, it was found that citarinostat preferentially induced histone crotonylation rather than acetylation in 2D10 cells, thereby confirming its classification as another candidate selective HDCRi (FIG. 4C). Conversely, compounds docking within the catalytic pocket were classified as dual-targeting HDACi (FIG. 10B). Among these, tucidinostat55uniquely induced strong histone acetylation with minimal crotonylation, which is opposite to citarinostat, suggesting it may act as a truly selective HDACi (FIG. 4C). Of note, this is the only possible candidate of selective HDACi with minimal HDCRi activity found after screening many currently available HDACi.

[0261] To assess the latency reversal activity of selective HD AC and HDCR inhibitors, citarinostat and tucidinostat were tested in the 2D 10 HIV latency model. Both compounds robustly induced HIV transcription (FIG. 4D), where citarinostat was stronger in latency reversal than tucidinostat at the doses ranging from 0.5.-1 pM. Citarinostat — a second-generation, orally bioavailableAttorney Docket No. 393976-00119

[0262] HDAC6-selective inhibitor bearing a hydroxamic acid ZBG — typically inhibits HDAC6 to induce a-tubulin hyperacetylation56.

[0263]

[0264] However, in 2D10 cells, citarinostat did not increase a-tubulin acetylation within 1-hour posttreatment (FIG. 10D), further indicating the HDCR selectivity of citarinostat.

[0265] Notably, dual-targeting HDACi also potently reversed HIV latency (FIG. 10E), consistent with previous reports of HDACi functioning as LRAs. In primary CD4+T cells, HDCRi citarinostat selectively enhanced histone crotonylation over acetylation even within 30 minutes of treatment (FIG. 4E). In contrast, RGFP966 and mod-RGFP966 — weaker LRAs (FIG.3A, 4D) — only weakly induced crotonylation at this early timepoint, with RGFP966 showing minimal activity. However, in contrast to its activity in the Jurkat model of latency, tucidinostat failed to induce either acetylation or crotonylation 30 minutes post-treatment in the primary CD4+T cell model of latency (FIG. 4E).

[0266] In primary CD4+T cells, HDCRi citarinostat selectively enhanced histone crotonylation over acetylation even within 30 minutes of treatment (Fig. 4E). In contrast, RGFP966 and mod-RGFP966, weaker LRAs compared to citarinostat (Fig. 3A), only weakly induced crotonylation at this early timepoint, with RGFP966 showing minimal activity. However, in contrast to its activity in the Jurkat model of latency, tucidinostat failed to induce either acetylation or crotonylation 30 minutes post-treatment in the primary CD4+T cell model of latency (Fig. 4E).

[0267] Recent discoveries have identified diverse short-chain lysine acylations on histones, including not only acetylation and crotonylation but also butyrylation, propionylation, and L-lactylation. Recognizing the diversity of histone acylation modifications21, it was sought to investigate whether the HDCRi disclosed herein were truly selective for decrotonylase activity over other acylations. Analysis of histone propionylation, lactylation, and butyrylation activity revealed that RGFP966, mod-RGFP966, and citarinostat induced minimal changes in these acylation modifications in both 2D 10 cells (FIG. 10E) and primary CD4+T cells (FIG. 4F). Together, these results indicate thatAttorney Docket No. 393976-00119

[0268] HDACi docking outside the catalytic pocket of HDAC3 may be the key to the selectivity of HDCRi.

[0269] Pharmacological approaches in cells are complicated by the potential co-expression of multiple HDACs, some of which possess dual deacetylase and decrotonylase activities (see W. Wei, X. Liu, J. Chen, S. Gao, L. Lu, H. Zhang, G. Ding, Z. Wang, Z. Chen, T. Shi, J. Li, J. Yu, J. Wong, Class I histone deacetylases are major histone decrotonylases: evidence for critical and broad function of histone crotonylation in transcription. Cell Res 27, 898-915 (2017)). To definitively dissect these enzymatic activities in the context of inhibitors, a well-controlled in vitro biochemical assay using purified HDAC3 and defined acylated substrates (acetylated and crotonylated) is required. While numerous commercial kits exist for quantifying classic HDAC deacetylase activity, no equivalent direct assay is available for measuring decrotonylase (HDCR) activity. Therefore, we adapted a published in vitro decrotonylation / deacetylation assay (see R. Fellows, P. Varga-Weisz, In vitro Enzymatic Assays of Histone Decrotonylation on Recombinant Histones. Bio Protoc 8, (2018)). This method involves incubating purified HDAC3 with crotonylated or acetylated histone substrates, followed by detection of the remaining acyl mark using site-specific antibodies. Incubation of crotonylated histone H3 with HDAC3 / NCOR1 (0.3 mg / mL) reduced signal intensity for H3K18cr, H3K27cr, and, to a lesser extent, pan-acetylation marks, confirming expected enzymatic activity (Figs. 15A and 15B). In this system, citarinostat potently inhibited the decrotonylase activity of HDAC3, increasing H3K18cr and H3K27cr levels in a dosedependent manner (effective from 0.8 pM). In contrast, it only slightly attenuated deacetylase activity at a significantly higher concentration (6.3 pM) (Figs. 15A and 15B). The inventors further tested higher enzyme concentrations (0.45 and 0.6 mg / mL HDAC3 / NCOR1) to amplify the deacetylase signal. Under these conditions, HDAC3 / NCOR markedly reduced histone acetylation. Even that, citarinostat' s inhibition of deacetylase activity remained minimal. This differential inhibition profile validates citarinostat’ s selectivity for decrotonylation over deacetylation. Collectively, these results suggest that inhibitors targeting sites outside the canonical catalytic pocket of HDAC3 may be key to achieving selective decrotonylase inhibition.

[0270] Citarinostat binds a conserved external site on HDAC3 and HDAC8 to selectively inhibit decrotonylase activity

[0271] Attorney Docket No. 393976-00119

[0272] Citarinostat is a potent biochemical inhibitor of HDAC6 but shows reduced efficacy against the nuclear Class I HDACs (HDAC1, HDAC2, HDAC3, and HDAC8) (see P. Huang, I. Almeciga-Pinto, M. Jarpe, J. H. van Duzer, R. Mazitschek, M. Yang, S. S. Jones, S. N. Quayle, Selective HD AC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models), all of which reported possess dual deacetylase and decrotonylase activities (see W. Wei, X. Liu, J. Chen, S. Gao, L. Lu, H. Zhang, G. Ding, Z. Wang, Z. Chen, T. Shi, J. Li, J. Yu, J. Wong, Class I histone deacetylases are major histone decrotonylases: evidence for critical and broad function of histone crotonylation in transcription. Cell Res 27, 898-915 (2017)). To investigate whether citarinostat's non-canonical binding mode, targeting sites outside the catalytic pocket of HDAC3, is conserved across other Class I members, we performed comparative molecular docking analyses against HDAC1, HDAC2, HDAC3, and HDAC8. The pan-inhibitor SAHA, with its well-characterized zinc-chelating binding mode, served as an internal control.

[0273] The inventors docking protocol reliably reproduced the canonical binding mode: SAHA consistently occupied the catalytic pocket across all four HDACs, engaging in expected hydroxamate-Zn2+coordination and pocket interactions (Fig. 16A). Two-dimensional interaction maps further confirmed this conserved binding pattern, with key shared residues highlighted. In contrast, citarinostat exhibited a distinct and reproducible binding profile. For all four HDAC isoforms, the top-ranked docking poses localized outside the canonical catalytic pocket, aligning with the external, cap-proximal binding mode we initially observed for HDAC3 (Fig. 16B).

[0274] Analysis of interaction diagrams revealed a conserved set of surface residues that mediate citarinostat binding across the isoforms. This consistent outside-pocket placement suggests that citarinostat engages a shared structural feature on the HDAC surface rather than the deep catalytic tunnel, potentially explaining its unique functional selectivity.

[0275] To determine whether citarinostat differentially inhibits the dual enzymatic activities of Class I HDACs, the inventors extended the in vitro decrotonylation / deacetylation assay to HDAC2 and HDAC8, since their in vitro study showed that HDAC1 had minimal activity in the inhibition of Tat-transactivation of HIV in the TZM-bl reporter model. The inventors first confirmed that both HDACs possess the hypothesized dual activity, effectively removing acetyl and crotonyl marks from histone substrates. Subsequent testing with citarinostat revealed a potent and selective inhibition of decrotonylase activity. In HDAC2, this inhibition elevated histone crotonylation levels at concentrations above 0.4 pM. Notably, in HDAC8, citarinostat caused a marked dose-Attorney Docket No. 393976-00119

[0276] dependent increase in H3K18Cr and H3K27Cr levels at dosages between 0.4-6.3 pM. In contrast, citarinostat's effect on deacetylase activity was markedly weaker for both HDAC isoforms, requiring significantly higher concentrations for only partial attenuation (12.5 pM for HDAC2 and 6.3 pM for HDAC8) (Figs. 16C, 16D).

[0277] To determine if HDAC3 is required for citarinostat to induce histone crotonylation, the inventors performed CRISPR-Cas9 knockout of HDAC3 in 2D10 cells. Specific loss of HDAC3 protein, without affecting the HDAC1, HDAC2, or HDAC8 level, was confirmed. Following HDAC3 knockout, the ability of citarinostat, RGFP966, and mod-RGFP966 to increase histone crotonylation was not completely abolished, producing an effect slightly above the DMSO control (Fig. 16E). This result indicates that citarinostat can elevate crotonylation through other HDACs in addition to HDAC3.

[0278] Given that citarinostat also targets the decrotonylase activity of HDAC8 (Fig. 16D), in addition to HDAC3 (Fig. 15A), the inventors employed YX968, an HDAC3 / HDAC8 dual PROTAC, to degrade both enzymes (see Y. Xiao, S. Hale, N. Awasthee, C. Meng, X. Zhang, Y. Liu, H. Ding, Z. Huo, D. Lv, W. Zhang, M. He, G. Zheng, D. Liao, HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation. Cell Chem Biol 30, 1421-1435 el412 (2023)). The inventors first confirmed that 1-20 nM YX968 (MedChemExpress) selectively degraded HDAC3 and HDAC8, but not HDAC1 and HDAC2, in 2D10 cells, unless the dosage was higher than 50 nM. Therefore, we pre-treated 2D 10 cells with DMSO or 20 nM YX968 for 24 h. Following drug washout, cells were further treated with selected HDACi for another 30 min. Upon HDAC3 / 8 degradation, the ability of citarinostat, RGFP966, and mod-RGFP966 to increase histone crotonylation was abolished, with effects comparable to the DMSO control (Fig. 16F).

[0279] This result indicates that citarinostat elevates crotonylation primarily through the inhibition of HDAC3 and HDAC8, but probably not HDAC2.

[0280] E. Exploring the unique docking profile to predict new selective HDCRi

[0281] If the unique docking profile of compounds outside the HDAC3 catalytic pocket is a prerequisite for effective HDCRi, one should identify other selective HDCRi based on this unique docking profile. To this end, it was sought virtual screening of compound libraries with 1101 FDA-approved compounds from the PubChem database. Of these, 743 compounds exhibited binding poses outside the HDAC3 catalytic pocket, suggesting potential selectivity as HDCRi candidates.

[0282] Attorney Docket No. 393976-00119

[0283] To refine this selection, the inventors prioritized compounds based on binding affinity scores and interaction patterns. The three highest-scoring compounds — lonafamib, olaparib, and deferasirox — were chosen for further evaluation. These compounds demonstrated favorable docking energies ranging from -9.9 to -8.0 kcal / mol, indicating strong binding interactions (FIG.

[0284] 11A). The docking analysis revealed that these selected compounds preferentially interacted with residues outside the enzymatic ZBP. Strikingly, lonafamib37and olaparib58induced HIV transcription from latency, whereas deferasirox59failed to elicit any reactivation (FIG. 11B).

[0285] Further biochemical analysis revealed that lonafarnib and olaparib increased histone crotonylation in a dose-dependent manner, aligning with their proposed role as HDCRi that block decrotonylation. In contrast, deferasirox barely modulated histone crotonylation, thus no HIV transcription was enhanced or inhibited (FIG. 11C). Notably, neither lonafarnib nor olaparib altered global levels of histone acetylation, butyrylation, propionylation, or L-lactylation (FIG.

[0286] 11C), supporting the hypothesis that compounds docking outside the HDAC3 catalytic pocket lack intrinsic broad-spectrum acylation modulation. Lonafarnib is a farnesyltransferase (FTase) inhibitor, which shows some activity in disrupting latent HIV60(Abstract 38 in The 6thHIV Persistence During Therapy International Workshop). However, the mechanism of FTase-induced latency reversal is elusive. The data here discovered an unexpected activity of FTase inhibitor lonafarnib as a selective HDCRi. Collectively, these results further support the premise that the region or structure just outside the HDAC3 catalytic pocket is critical for HDCR activity in HD AC 3 protein.

[0287] F. Amino acids surrounding the pocket sites are critical in maintaining HDCR activity in HDAC3

[0288] The structural analyses disclosed herein revealed that selective HDCRi preferentially dock adjacent to, but outside, the ZBP of HDAC3. This distinct docking profile suggests that the local structural environment surrounding the catalytic site — rather than the zinc-binding domain itself — plays a critical role in mediating HDCRi selectivity. To map these interactions, selective HDCRi compounds were modeled within the HDAC3 crystal structure, identifying key amino acid residues (D57, QI 13, R265, and R301) outside the ZBP that are essential for histone decrotonylase activity (FIG. 5A). To validate their mechanistic role, a site-directed HDAC3 mutants (D57A, Q113A, R265A, R301A) was generated and their decrotonylation activities were assessed.

[0289] Attorney Docket No. 393976-00119

[0290] Strikingly, all mutants exhibited a near-complete loss of histone decrotonylation activity, thus increasing crotonylation levels compared with WT-HDAC3 (FIG. 5B). Importantly, these HDAC3 mutations had minimal effects on other histone acylation marks compared to WT HDAC3 (e.g., acetylation, L-lactylation, butyrylation, and propionylation) (FIG. 5B), confirming their selective role in decrotonylation, highlighting their essential role in controlling the switch from HD AC to HDCR enzyme activity within HDAC3. These results redefine the structural basis of HDAC3 substrate specificity, emphasizing the importance of peripheral catalytic site architecture in mediating the selective enzymatic activity of HDCR.

[0291] G. HDCRi selectively induces histone crotonylation, but not acetylation, at the HIV LTR during latency reversal

[0292] The data disclosed herein shows that HDCRi disrupts latent HIV by selectively targeting HDCR to induce histone crotonylation, without affecting acetylation. However, these effects were initially assessed at the total histone protein level. To determine whether HDCRi preferentially targets crotonylation surrounding the HIV promoter, the histone crotonylation markers H3K18Cr and H3K27Cr were investigated, along with global lysine acetylation (panKac), via ChIP assays12. Results revealed that citarinostat significantly elevated H3K18Cr and H3K27Cr levels at the HIV promoter LTR and Nuc 1 regions. Consistent with prior findings, RGFP966 demonstrated a trend toward enhancing H3K27Cr; however, the observed increase did not reach statistical significance. Notably, both HDCRi compounds had minimal effect on acetylation near the HIV promoter (FIG.

[0293] 6A). Taken together, these findings indicate that selective HDCRi enhances crotonylation at the HIV promoter, highlighting this unique mechanism as a driver of HIV latency reversal.

[0294] H. Suppression by selective HDCRi may delay HIV re-entry into latency in the primary CD4+T cells

[0295] If HDCR is needed for establishing HIV latency, its suppression should prevent or delay viral entry into latency61. The findings disclosed herein demonstrate that selective HDCRi act as potent HIV LRAs. It was hypothesized that blocking HDCR activity could inhibit proviral transition into latency. To test this, a primary CD4+T cell model33was employed as shown in FIG. 1A, wherein cells were reactivated via anti-CD3 / anti-CD28 stimulation for two days, followed by HDCRi

[0296] Attorney Docket No. 393976-00119

[0297] treatment. In DMSO-treated controls, GFP-negative cells progressively increased, reflecting natural latency establishment after removal of anti-CD3 / anti-CD28, with 93% entering latency by day 7. In contrast, mod-RGFP966 reduced latent infection to 68% (FIG. 6B), while in a separate primary CD4+T cell clone, citarinostat decreased latently infected cells from 97% (DMSO control) to 76% (FIG. 6C). These results demonstrate that disruption of latent HIV at the time of latency establishment by HDCRi may suppress HIV latency re-entry.

[0298] I. Inhibiting HDCR disrupts latent HIV in resting CD4+T cells from people with HIV

[0299] To further examine whether the disclosed newly characterized selective HDCRi could be used in HIV cure studies, investigations disclosed herein extended to resting CD4+T cells from PWH on suppressive ART (n = 8, Table 1). Phorbol 12-myristate 13-acetate (PMA) and ionomycin, serving as positive controls, induced HIV transcription in 6 of 8 samples, confirming the responsiveness of the model and consistent with previous observations that while potent in latency reversal, PMA / Iono may disrupt latent HIV in all PWH-derived CD4+T cells62. The classical dualtargeting HDACi SAHA, induced HIV transcription in three of eight samples, demonstrating limited efficacy as previously reported14. The selective but weaker HDCRi RGFP966 and modified RGFP966 induced latency reversal in 2-3 of 8 samples. Notably, citarinostat, the most potent HDCRi disclosed herein, robustly reactivated latent HIV in seven of the eight individuals tested (FIG. 7A, FIG. 12a). In most cases, it was even more potent in disrupting latent HIV than PMA / Ionomycin. In summary, citarinostat significantly outperformed any other compound in inducing HIV transcription from latency, presenting a remarkable potential for latency reversal in resting CD4+T cells from PWH on ART (FIGs. 7B and 12B). Additionally, stimulation with citarinostat increased cell-free HIV RNA levels in the culture supernatants (n = 3), further validating its potency in latency disruption (FIG. 7C). These results collectively suggest that selectively targeting HDCR can reverse HIV latency, further supporting the unique role of HDCR in regulating HIV latency in resting CD4+ T cells.

[0300] J. Selective HDCRi can disrupt latent HIV in non-T cells isolated from PWH or NHP on ART

[0301] Attorney Docket No. 393976-00119

[0302] The data presented herein underscores the pivotal role of HDCRi in reversing HIV latency within T-cell reservoirs. However, HIV reservoirs also persist in tissue myeloid cells. For example, the inventors recently characterized a stable HIV reservoir in the brain MG28, which may differ from T cell reservoirs regarding epigenetic regulation63. Reversal of HIV latency in both T cell and non-T cell reservoirs is critical for future cure strategies. Using the same approaches as before28, the inventors isolated viable brain MG from PWH or NHPs on ART (FIG.7D). As shown in FIG.7E, selective HDCRi RGFP966 was able to disrupt latent HIV to induce HIV transcription in all tested samples (n = 4), while both the dual-targeting epigenetic LRA SAHA and NaCr showed limited efficacy, except in the Pl sample treated with NaCr. Furthermore, citarinostat significantly induced HIV transcription from latent infected human brain MG (Fig. 17). Expanding the disclosed investigation in SIV-infected NHPs on ART (n=3) or those with SIV control after ART interruption (n=3), brain MG were isolated from the fresh brain tissues and cultured for 1-2 weeks for recovery before LRA treatment. We found that selective HDCRi citarinostat significantly upregulated SIV transcription in isolated brain microglia, and increased SIV RNA release from these cells (FIGs. 7F and 13).

[0303] Of note, two animals, NHP1 and 3 from CNPRC, had plasma VL between 290 and 400 copies / mL at the time of necropsy despite continuous ART. Despite that, cell-associated SIV RNA was undetectable in brain MG, but SIV RNA expression and viral release were induced by citarinostat (FIG. 7F). Animals 4, 5, 6 from ONRPC experienced ART interruption but maintained low plasma viremia for a prolonged time and thus were considered as post-therapy controllers. Nevertheless, SIV transcription in brain MG remained extremely low in these cells, as well as in culture supernatants, but latent SIV was induced by citarinostat (FIG. 7F). Together, these findings underscore the unique role of HDCR in HIV or SIV latency in brain MG in PWH on suppressive ART, or NHPs. By targeting diverse cellular reservoirs in both the periphery and the CNS, selectively inhibiting HDCRi offers a pathway toward comprehensive latency reversal.

[0304] IV. Results of Additional Studies

[0305] The establishment of HIV latency is controlled by multitude of regulatory mechanisms, including various signaling pathways that influence histone modifications such as deacetylation and methylation of histone tails surrounding the HIV promoter. Disclosed herein, the inventors demonstrate that HIV latency is uniquely regulated by an additional epigenetic mechanism,Attorney Docket No. 393976-00119

[0306] specifically histone decrotonylation, independent of other acylation modifications. This regulation occurs in T cells, and non-T cells such as brain microglia, part of the immune-privileged CNS, and a stable HIV myeloid cell reservoir the inventors have recently characterized28. These findings further show that several amino acids surrounding the ZBP, but not within it, are critical for maintaining selective HDCR activity in association with HDAC3 enzyme.

[0307] A central contribution of this work is the definitive identification of HDAC3 and HDAC8 as the major HDCR enzymes and the primary cellular targets mediating citarinostat's pro-crotonylation effect. This conclusion was established through a stepwise functional dissection of class I HDACs, enzymes known to possess HDCR activity (see W. Wei, X. Liu, J. Chen, S. Gao, L. Lu, H. Zhang, G. Ding, Z. Wang, Z. Chen, T. Shi, J. Li, J. Yu, J. Wong, Class I histone deacetylases are major histone decrotonylases: evidence for critical and broad function of histone crotonylation in transcription. Cell Res 27, 898-915 (2017).). Initial experiments using HDAC3 mutants defective in deacetylase activity confirmed that HDAC3 suppresses Tat-mediated HIV transcription via its decrotonylase function. In contrast, parallel analysis of HD AC 1 did not show a similar suppressive function. Due to the possibility that other HDACs possess dual activity, including HDAC2 and HDAC8, which might compensate for the loss of decrotonylation activity during our cellular analyses of HDCR chemical biology in HDAC3 (see K. S. Keedy, N. M. Archin, A. T. Gates, A. Espeseth, D. J. Hazuda, D. M. Margolis, A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol 83, 4749-4756 (2009)), the inventors employed orthogonal genetic and chemical approaches. CRISPR-Cas9 knockout of HDAC3 only partially reduced citarinostat's ability to induce histone crotonylation, suggesting compensatory activity from other HDACs. The inventors therefore used the dual PROTAC YX968 to degrade both HDAC3 and HDAC8. This intervention completely abolished citarinostat's effect, providing compelling evidence that citarinostat elevates crotonylation primarily through HDAC3 and HDAC8, distinguishing their roles from those of HDAC2 in this cellular context.

[0308] Although it was not completely unexpected, many currently available HDACi, aside from tucidinostat, demonstrated strong activities in inducing both acetylation and crotonylation within 30 minutes of exposure. This suggests that previous studies on HIV latency reversal using these HDACi may be partially mediated by the suppression of HDCR as well (see N. M. Archin, A. L. Liberty, A. D. Kashuba, S. K. Choudhary, J. D. Kuruc, A. M. Crooks, D. C. Parker, E. M.

[0309] Attorney Docket No. 393976-00119

[0310] Anderson, M. F Kearney, M. C. Strain, D. D. Richman, M. G. Hudgens, R. J. Bosch, J. M. Coffin, J. J. Eron, D. J. Hazuda, D. M. Margolis, Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485 (2012); K. Shirakawa, L. Chavez, S. Hakre, V. Calvanese, E. Verdin, Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 21, 277-285 (2013); D. G. Wei, V. Chiang, E. Fyne, M. Balakrishnan, T. Barnes, M. Graupe, J. Hesselgesser, A. Irrinki, J. P. Murry, G. Stepan, K. M. Stray, A. Tsai, H. Yu, J. Spindler, M. Kearney, C. A. Spina, D. McMahon, J. Lalezari, D. Sloan, J. Mellors, R. Geleziunas, T. Cihlar, Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 10, el004071 (2014)), a mechanism likely also involved in their activity in cancer (see R. Irimia, P. P. Piccaluga, Histone Deacetylase Inhibitors for Peripheral T-Cell Lymphomas. Cancers (Basel) 16, (2024)) and acute kidney injury therapy (see Y. He, Y. Xie, T. Zhou, D. Li, X. Cheng, P. Yang, C. Luo, Y. Liu, M. Guo, Q. Wan, P. Yan, C. Gao, Y. Y. Zhang, X. D. Sun, Y. Xu, W. Huang, Sodium Crotonate Alleviates Diabetic Kidney Disease Partially Via the Histone Crotonylation Pathway. Inflammation 48, 254-275 (2025); J. M. Martinez-Moreno, M. Fontecha-Barriuso, D. Martin-Sanchez, J. Guerrero-Mauvecin, E. Goma-Garces, B. Fernandez-Fernandez, S. Carriazo, M. D. Sanchez-Nino, A. M. Ramos, M. Ruiz-Ortega, A. Ortiz, A. B. Sanz, Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease. Int J Mol Sci 21, (2020)). This highlights the potential role in mediating active epigenetic regulation, as observed in our study. It may be worthwhile to revisit earlier studies to more accurately delineate the mechanisms of epigenetic regulation in HIV latency, cancer therapy, or kidney disease treatments. While tucidinostat is selective for HD AC over HDCR and potent in latency reversal in 2D 10 cells, it was weak in inducing histone acetylation in primary CD4+T cells when the cells were treated for 30 min. It may warrant further investigation with a longer treatment time. Alternatively, other acylation modifications could be involved in its latency reversal. However, dissecting the specific roles of individual acylation in regulating HIV latency and carcinogenesis remains a challenge, as the same enzymes catalyze many different histone acylations (see B. R. Sabari, D. Zhang, C. D. Allis, Y. Zhao, Metabolic regulation of gene expression through histone acylations. Nat Rev Mol Cell Biol 18, 90-101 (2017)), which may or may not be controlled by identical enzyme pockets or sub-structures, as we have shown for HDCR.

[0311] Attorney Docket No. 393976-00119

[0312] Notably, in the TZM-bl reporter analysis from the inventors, it was observed that, unlike HDAC3, HDAC1 does not appear to contribute to the suppression of Tat-transactivation of HIV (data not shown). Thus, this disclosure focuses on HDAC3 decrotonylation in the epigenetic regulation of HIV latency, although one cannot exclude the possibility that other HDACs, including HDAC1, might compensate for the loss of decrotonylation activity during the analyses of HDCR chemical biology in HDAC364. Regardless, the high efficacy of the disclosed newly identified selective HDCRi in disrupting HIV latency in both T cells and non-T cells strongly supports the critical role of HDCR in regulating HIV latency.

[0313] Previous studies on HIV latency reversal using HD ACi14,46,63suggest that these compounds may also be useful for treating cancer66and acute kidney injury therapy67,68. This highlights the potential role in mediating active epigenetic regulation, as observed herein. It may be worthwhile to further investigate the mechanisms of epigenetic regulation in HIV latency, cancer therapy, or kidney disease treatments. As already mentioned above, tucidinostat was selective for HD AC over HDCR and was potent in latency reversal in 2D 10 cells, even thought it was weak in inducing histone acetylation in primary CD4+T cells when the cells were treated for 30 min. Alternatively, other acylation modifications could be involved in its latency reversal. However, dissecting the specific roles of individual acylation in regulating HIV latency and carcinogenesis remains a challenge, as the same enzymes catalyze many different histone acylations21, which may or may not be controlled by identical enzyme pockets or sub-structures, as shown for HDCR.

[0314] Another feature of this disclosure is the examination of fluorine substitution in the benzamide ZBG of HDCR inhibitors, where the inventors characterized the unique and unexpected role of fluorine in the activities of the benzamide ring in HDCRi during HIV latency reversal. The incorporation of fluorine in RGFP966, an HDAC3 inhibitor, was originally aimed at optimizing its pharmacological properties, including enhanced binding affinity to HDAC3, improved potency in suppressing HDAC3 deacetylation activity, and metabolic stability52,33. Interestingly, the removal of the fluorine atom from the benzamide ZBG of RGFP966, enhances its efficacy and reduces cellular toxicity in T cells, suggesting that defluorination might increase the potency of HDCRi inhibition and facilitate the reactivation of latent HIV. Fluorine typically participates in weak intramolecular interactions, such as C-F--H hydrogen bonds or may influence the conformation of the ZBG. In RGFP966, fluorine likely stabilizes the orientation of the 2-amino-4-fluorophenyl group, optimizing its interaction with the zinc ion and the HDAC3 active site. ThisAttorney Docket No. 393976-00119

[0315] finding suggests that removing the fluorine atom from the benzamide ring could shift the selectivity of RGFP966 from HD AC to HDCR, thereby enhancing its potency in disrupting HIV latency. These results may inform the design of more specific and effective HDCR inhibitors with improved pharmacological profiles and reduced toxicity.

[0316] To put it in another way, while fluorine introduction is a common strategy to optimize pharmacological properties, the inventors characterize the unique and unexpected role of fluorine in the activities of the benzamide ring in HDCRi during HIV latency reversal. The incorporation of fluorine in RGFP966, an HDAC3 inhibitor, was originally aimed at optimizing its pharmacological properties, including enhanced binding affinity to HDAC3, improved potency in suppressing HDAC3 deacetylation activity, and metabolic stability. Interestingly, the removal of the fluorine atom from the benzamide ZBG of RGFP966 appears to enhance its efficacy and reduce cellular toxicity in T cells, suggesting that defluorination might increase the potency of HDCRi inhibition and facilitate the reactivation of latent HIV. Furthermore, for mod-mocetinostat, fluorination (creating mod-mocetinostat) reduced its potency to reverse HIV latency at lower concentrations (0.5-2 pM). As already mentioned above, fluorine typically participates in weak intramolecular interactions, such as C-F—H hydrogen bonds, which may influence the conformation of the ZBG. In RGFP966, fluorine likely stabilizes the orientation of the 2-amino-4-fluorophenyl group, optimizing its interaction with the zinc ion and the HDAC3 active site. This finding suggests that removing the fluorine atom from the benzamide ring could shift the selectivity of RGFP966 from HD AC to HDCR, thereby enhancing its potency in disrupting HIV latency. These results may inform the design of more specific and effective HDCR inhibitors with improved pharmacological profiles and reduced toxicity.

[0317] A structural analysis revealed an important feature of HDCRi: they preferentially dock adjacent to, rather than within, the ZBP of HDAC3. This binding mode suggests that HDCRi may act via allosteric modulation of the catalytic site, rather than direct inhibition. The rigid, extended architecture of their ZBG structures could induce conformation changes in the HDAC3 catalytic pocket21, that selectively impair decrotonylation activity without broadly inhibiting other deacylase functions. This model — targeting a region surrounding the ZBP — offers a mechanistic framework for the rational discovery of novel, truly selective HDCRi. Indeed, the inventors have identified additional selective HDCRi within FDA-approved drug libraries using this docking paradigm. Two such candidates, lonafamib and olaparib, were predicted to bind outside the

[0318] Attorney Docket No. 393976-00119

[0319] HDAC3 catalytic pocket and exhibited no broad-spectrum deacylation activities, reinforcing the predictive value of the disclosed docking model.

[0320] Furthermore, the inventor’s structural analyses revealed a key mechanism underlying HDCRi selectivity. Comparative molecular docking demonstrated that citarinostat exhibits a conserved non-canonical binding mode across HDAC1, HDAC2, HDAC3, and HDAC8. Unlike the paninhibitor SAHA, which consistently occupies the ZBP, citarinostat preferentially docks to an external, cap-proximal site, engaging a shared surface feature on these enzymes. The rigid, extended architecture of their ZBG structures could induce conformation changes in the enzyme’s catalytic pocket, selectively impairing decrotonylation activity without broadly inhibiting other deacylase functions. This model provides a mechanistic framework for rational discovery, which we validated by identifying additional selective HDCRi, such as lonafarnib and olaparib, from FDA-approved compound libraries using the same docking paradigm. Their predicted external binding and lack of broad-spectrum deacylation activity reinforce the predictive value of targeting this conserved exosite for selective HDCR inhibition.

[0321] Although no decrotonylation-specific substructure has been specifically identified in any HDAC, the disclosed model posits the existence of a secondary hydrophobic groove or adjacent pocket — approximately 5-7 A in length — that could accommodate the crotonyl chain (CH3-CH=CH-C=O"). Such a site may stabilize the crotonyl group via 71- it interactions and include a distinct catalytic residue for hydrolysis, separate from the zinc. Structural validation — such as cocrystallization of HDAC3 with HDCRi or crotonyl-lysine — is needed to clarify these binding poses and refine the inventor’s mechanistic understanding.

[0322] Modeling a few selective HDCRi within the HDAC3 crystal structure identified four key residues (D57, QI 13, R265, and R301) in the catalytic site’s peripheral architecture. Mutagenesis of these residues abolished HDAC3’s decrotonylase activity, underscoring their essential role as a molecular selectivity filter. These findings redefine the structural basis of HDAC3 enzymatic specificity and offer therapeutic opportunities, due to the high potency of the selective HDCRi citarinostat discovered in this study disclosed herein. Further, histone crotonylation dynamics contribute to epigenetic silencing that may maintain HIV latency. By targeting HDAC3’s decrotonylation activity — either through inhibitors mimicking the mutagenesis-induced disruption or allosteric modulation of these residues — latent viral reservoirs could be better reactivated, enabling a follow-up immune clearance and advancing strategies for an HIV functional cure.

[0323] Attorney Docket No. 393976-00119

[0324] Together, this work advances the inventor’s understanding of HDCR activity in regulating HIV latency. The chemical biology approaches used herein are beneficial for designing next-generation epigenetic inhibitors that target discrete histone-modifying activities with precision, offering therapeutic potential for diseases linked to aberrant crotonylation signaling.

[0325] Beyond enzymology, the inventors demonstrate that histone decrotonylation at the HIV LTR is an epigenetic mechanism that influences HIV latency. Selective HDCRi potently disrupts HIV latency not only in T cells but also non-T cells, like brain MG isolated from PWH on suppressive ART, suggesting that histone decrotonylation regulates HIV latency across immune cell types. These observations were similarly replicated in the NHP model of HIV persistence in vivo.

[0326] It is challenging to secure a rapid autopsy that allows isolation of viable brain MG2829. However, the selective HDCRi RGFP966 is able to penetrate the brain69and data disclosed herein suggests that selective inhibition of HDAC3 decrotonylase activity may reactivate latent HIV across multiple tissue compartments, including the CNS, thereby enhancing HIV cure strategies.

[0327] In summary, the findings disclosed herein highlight the unique role of histone decrotonylation in regulating HIV latency in both T cells and brain MG. The discovery of selective HDCRi and amino acids essential for HDCR surrounding the ZBP at HDAC3 provides an opportunity to unravel the molecular mechanism of HDCR in regulating HIV transcription and latency.

[0328] V. Pharmaceutical Formulation / Dosing / mode of administration

[0329] In certain embodiments, compounds, prodrugs or salts of Formula (I) disclosed herein, are combined with one or more additional agents to form pharmaceutical compositions. In some embodiments, compounds of F Formula (1) are already in the form of a prodrug. Pharmaceutical compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers including excipients and auxiliaries, which facilitate processing of the active compounds into preparations, which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Additional details about suitable excipients for pharmaceutical compositions described herein may be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 1975; Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New

[0330] Attorney Docket No. 393976-00119

[0331] York, N. Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), herein incorporated by reference for such disclosure.

[0332] A pharmaceutical composition, as used herein, refers to a mixture of a compound or salt or prodrug of Formula (I) with any suitable substituents and functional groups disclosed herein, with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and / or excipients. The pharmaceutical composition facilitates the administration of the compound to an organism. In practicing the methods of treatment or use provided herein, therapeutically effective amounts of compounds described herein are administered in a pharmaceutical composition to a mammal having a disease, disorder, or condition to be treated. In some embodiments, the mammal is a human. A therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. The compounds or salts of Formula (I) with any suitable substituents and functional groups disclosed herein, can be used singly or in combination with one or more additional therapeutic agents as components of mixtures (as in combination therapy).

[0333] The pharmaceutical formulations described herein can be administered to a subject by multiple administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal, or transdermal administration routes. Moreover, the pharmaceutical compositions described herein, which include a compound of Formula (I) with any suitable substituents and functional groups disclosed herein, can be formulated into any suitable dosage form, including but not limited to, aqueous oral dispersions, liquids, gels, syrups, elixirs, slurries, suspensions, aerosols, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, and capsules.

[0334] One may administer the compounds and / or compositions disclosed herein as long-acting formulations administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with a specific antibody. In addition, the drug may be provided in the form of a rapid release formulation, in the form of an extended-release formulation, or in the form of an intermediate release formulation.

[0335] Pharmaceutical compositions including a compound described herein may be manufactured in a conventional manner, such as, by way of example only, by means of

[0336] Attorney Docket No. 393976-00119

[0337] conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.

[0338] The pharmaceutical compositions will include at least one compound of Formula (I) disclosed herein, as an active ingredient in free-acid or free-base form, or in a pharmaceutically acceptable salt form.

[0339] In some embodiments, compositions provided herein may also include one or more preservatives to inhibit microbial activity. Suitable preservatives include quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.

[0340] In some embodiments, the pharmaceutical solid dosage forms described herein can include a compound of Formula (I) and one or more pharmaceutically acceptable additives such as a compatible carrier, binder, fdling agent, suspending agent, flavoring agent, sweetening agent, disintegrating agent, dispersing agent, surfactant, lubricant, colorant, diluent, solubilizer, moistening agent, plasticizer, stabilizer, penetration enhancer, wetting agent, anti-foaming agent, antioxidant, preservative, or one or more combination thereof. In still other aspects, using standard coating procedures, such as those described in Remington's Pharmaceutical Sciences, 20th Edition (2000), a film coating is provided around the formulation of the compound described herein. In one embodiment, some or all of the particles of the compound described herein are coated. In another embodiment, some or all of the particles of the compound described herein are microencapsulated. In still another embodiment, the particles of the compound described herein are not microencapsulated and are uncoated.

[0341] Suitable carriers for use in the solid dosage forms described herein include, but are not limited to, acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerine, magnesium silicate, sodium caseinate, soy lecithin, sodium chloride, tricalcium phosphate, dipotassium phosphate, sodium stearoyl lactylate, carrageenan, monoglyceride, diglyceride, pregelatinized starch, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate stearate, sucrose, microcrystalline cellulose, lactose, mannitol and the like.

[0342] Suitable filling agents for use in the solid dosage forms described herein include, but are not limited to, lactose, calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose, cellulose powder, dextrose, dextrates, dextran, starches,

[0343] Attorney Docket No. 393976-00119

[0344] pregelatinized starch, hydroxypropylmethy cellulose (HPMC), hydroxypropylmethy cellulose phthalate, hydroxypropylmethylcellulose acetate stearate (HPMCAS), sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like.

[0345] Suitable disintegrants for use in the solid dosage forms described herein include, but are not limited to, natural starch such as corn starch or potato starch, a pregelatinized starch such as National 1551 or Amijel®, or sodium starch glycolate such as Promogel® or Explotab®, a cellulose such as a wood product, methylcrystalline cellulose, e.g., Avicel®, Avicel® PH101, Avicel® PHI 02, Avicel® PHI 05, Elcema® Pl 00, Emcocel®, Vivacel®, Ming Tia®, and Solka-Floc®, methyl cellulose, croscarmellose, or a cross-linked cellulose, such as cross-linked sodium carboxymethylcellulose (Ac-Di-Sol®), cross-linked carboxymethylcellulose, or cross-linked croscarmellose, a cross-linked starch such as sodium starch glycolate, a cross-linked polymer such as crospovidone, a cross-linked polyvinylpyrrolidone, alginate such as alginic acid or a salt of alginic acid such as sodium alginate, a clay such as Veegum® HV (magnesium aluminum silicate), a gum such as agar, guar, locust bean, Karaya, pectin, or tragacanth, sodium starch glycolate, bentonite, a natural sponge, a surfactant, a resin such as a cation-exchange resin, citrus pulp, sodium lauryl sulfate, sodium lauryl sulfate in combination starch, and the like.

[0346] Suitable binders in the solid dosage forms described herein include, but are not limited to, carboxymethylcellulose, methylcellulose (e.g., Methocel®), hydroxypropylmethylcellulose (e.g. Hypromellose USP Pharmacoat-603, hydroxypropylmethylcellulose acetate stearate (Aqoate HS-LF and HS), hydroxyethylcellulose, hydroxypropylcellulose (e g., Klucel®), ethyl cellulose (e.g., Ethocel®), and microcrystalline cellulose (e.g., Avicel®), microcrystalline dextrose, amylose, magnesium aluminum silicate, polysaccharide acids, bentonites, gelatin, polyvinylpyrrolidone / vinyl acetate copolymer, crospovidone, povidone, starch, pregelatinized starch, tragacanth, dextrin, a sugar, such as sucrose (e g., Dipac®), glucose, dextrose, molasses, mannitol, sorbitol, xylitol (e.g., Xylitab®), lactose, a natural or synthetic gum such as acacia, tragacanth, ghatti gum, mucilage of isapol husks, starch, polyvinylpyrrolidone (e.g., Povidone® CL, Kollidon® CL, Polyplasdone® XL- 10, and Povidone® K-12), larch arabogalactan, Veegum®, polyethylene glycol, waxes, sodium alginate, and the like.

[0347] Suitable lubricants or glidants for use in the solid dosage forms described herein include, but are not limited to, stearic acid, calcium hydroxide, talc, corn starch, sodium stearyl fumerate, alkali-metal and alkaline earth metal salts, such as aluminum, calcium, magnesium, zinc, stearicAttorney Docket No. 393976-00119

[0348] acid, sodium stearates, magnesium stearate, zinc stearate, waxes, Stearowet®, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, a polyethylene glycol or a methoxypolyethylene glycol such as Carbowax™, PEG 4000, PEG 5000, PEG 6000, propylene glycol, sodium oleate, glyceryl behenate, glyceryl palmitostearate, glyceryl benzoate, magnesium or sodium lauryl sulfate, and the like.

[0349] Suitable diluents for use in the solid dosage forms described herein include, but are not limited to, sugars (including lactose, sucrose, and dextrose), polysaccharides (including dextrates and maltodextrin), polyols (including mannitol, xylitol, and sorbitol), cyclodextrins and the like.

[0350] Suitable wetting agents for use in the solid dosage forms described herein include, for example, oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, quaternary ammonium compounds (e g., Polyquat 10®), sodium oleate, sodium lauryl sulfate, magnesium stearate, sodium docusate, triacetin, vitamin E TPGS and the like.

[0351] Suitable surfactants for use in the solid dosage forms described herein include, for example, sodium lauryl sulfate, sorbitan monooleate, polyoxyethylene sorbitan monooleate, polysorbates, polaxomers, bile salts, glyceryl monostearate, copolymers of ethylene oxide and propylene oxide, e.g., Pluronic® (BASF), and the like.

[0352] Suitable suspending agents for use in the solid dosage forms described here include, but are not limited to, polyvinylpyrrolidone, e g., polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30, polyethylene glycol, e.g., the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 5400 to about 7000, vinyl pyrrolidone / vinyl acetate copolymer (S630), sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, polysorbate-80, hydroxyethylcellulose, sodium alginate, gums, such as, e.g., gum tragacanth and gum acacia, guar gum, xanthans, including xanthan gum, sugars, cellulosics, such as, e.g., sodium carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, polysorbate-80, sodium alginate, polyethoxylated sorbitan monolaurate, polyethoxylated sorbitan monolaurate, povidone and the like.

[0353] Suitable antioxidants for use in the solid dosage forms described herein include, for example, e.g., butylated hydroxytoluene (BHT), sodium ascorbate, and tocopherol.

[0354] Attorney Docket No. 393976-00119

[0355] There is considerable overlap between additives used in the solid dosage forms described herein. Thus, the above-listed additives should be taken as merely exemplary, and not limiting, of the types of additives that can be included in solid dosage forms of the pharmaceutical compositions described herein.

[0356] Liquid formulation dosage forms for oral administration can be aqueous suspensions selected from the group including, but not limited to, pharmaceutically acceptable aqueous oral dispersions, emulsions, solutions, elixirs, gels, and syrups. See, e.g., Singh et al., Encyclopedia of Pharmaceutical Technology, 2nd Ed., pp. 754-757 (2002).

[0357] The pharmaceutical compositions described herein may include sweetening agents such as, but not limited to, acacia syrup, acesulfame K, alitame, anise, apple, aspartame, banana, Bavarian cream, berry, black currant, butterscotch, calcium citrate, camphor, caramel, cherry, cherry cream, chocolate, cinnamon, bubble gum, citrus, citrus punch, citrus cream, cotton candy, cocoa, cola, cool cherry, cool citrus, cyclamate, cylamate, dextrose, eucalyptus, eugenol, fructose, fruit punch, ginger, glycyrrhetinate, glycyrrhiza (licorice) syrup, grape, grapefruit, honey, isomalt, lemon, lime, lemon cream, monoammonium glyrrhizinate (MagnaSweet®), maltol, mannitol, maple, marshmallow, menthol, mint cream, mixed berry, neohesperidine DC, neotame, orange, pear, peach, peppermint, peppermint cream, Prosweet® Powder, raspberry, root beer, rum, saccharin, safrole, sorbitol, spearmint, spearmint cream, strawberry, strawberry cream, stevia, sucralose, sucrose, sodium saccharin, saccharin, aspartame, acesulfame potassium, mannitol, talin, sucralose, sorbitol, swiss cream, tagatose, tangerine, thaumatin, tutti fruitti, vanilla, walnut, watermelon, wild cherry, wintergreen, xylitol, or any combination of these flavoring ingredients, e.g., anise-menthol, cherry-anise, cinnamon-orange, cherry-cinnamon, chocolate-mint, honey-lemon, lemon-lime, lemon-mint, menthol-eucalyptus, orange-cream, vanilla-mint, and mixtures thereof.

[0358] Potential excipients for intranasal formulations include formulations solutions in saline, employing benzyl alcohol or other suitable preservatives, fluorocarbons, and / or other solubilizing or dispersing agents. See, for example, Ansel, H. C. et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, Sixth Ed. (1995). Preferably, these compositions and formulations are prepared with suitable nontoxic pharmaceutically acceptable ingredients. The choice of suitable carriers is highly dependent upon the exact nature of the nasal dosage form desired, e.g., solutions, suspensions, ointments, or gels. Nasal dosage forms generally contain large amounts of water in addition to the active ingredient. Minor amounts of other ingredients such as pH adjusters,

[0359] Attorney Docket No. 393976-00119

[0360] emulsifiers or dispersing agents, preservatives, surfactants, gelling agents, or buffering and other stabilizing and solubilizing agents may also be present. Preferably, the nasal dosage form should be isotonic with nasal secretions.

[0361] For administration by inhalation, the compounds described herein may be in the form as an aerosol, a mist or a powder. Pharmaceutical compositions described herein are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, di chlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, such as, by way of example only, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound described herein and a suitable powder base such as lactose or starch.

[0362] Buccal formulations that include compounds described herein may be administered using a variety of formulations, which include, but are not limited to, U. S. Pat. Nos. 4,229,447, 4,596,795, 4,755,386, and 5,739,136. In addition, the buccal dosage forms described herein can further include a bioerodible (hydrolysable) polymeric carrier that also serves to adhere the dosage form to the buccal mucosa. The buccal dosage form is fabricated so as to erode gradually over a predetermined time period, wherein the delivery of the compound is provided essentially throughout. Buccal drug delivery avoids the disadvantages encountered with oral drug administration, e.g., slow absorption, degradation of the active agent by fluids present in the gastrointestinal tract and / or first-pass inactivation in the liver. With regard to the bioerodible (hydrolysable) polymeric carrier, virtually any such carrier can be used, so long as the desired drug release profile is not compromised, and the carrier is compatible with the compounds described herein, and any other components that may be present in the buccal dosage unit. Generally, the polymeric carrier comprises hydrophilic (water-soluble and water-swellable) polymers that adhere to the wet surface of the buccal mucosa. Examples of polymeric carriers useful herein include acrylic acid polymers and co, e.g., those known as “carbomers” (Carbopol®, which may be obtained from B. F. Goodrich, is one such polymer). Other components may also be incorporated into the buccal dosage forms described herein include, but are not limited to, disintegrants, diluents, binders, lubricants, flavoring, colorants, preservatives, and the like. For buccal or

[0363] Attorney Docket No. 393976-00119

[0364] sublingual administration, the compositions may take the form of tablets, lozenges, or gels formulated in a conventional manner.

[0365] Transdermal formulations described herein may incorporate certain pharmaceutically acceptable excipients, which are conventional in the art. In some embodiments, formulations suitable for transdermal administration of compounds described herein may employ transdermal delivery devices and transdermal delivery patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and / or dispersed in a polymer or an adhesive.

[0366] Formulations suitable for intramuscular, subcutaneous, or intravenous injection may include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents, or vehicles including water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, cremophor and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Formulations suitable for subcutaneous injection may also contain additives such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the growth of microorganisms can be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.

[0367] For intravenous injections, compounds described herein may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally recognized in the field. For other parenteral injections, appropriate formulations may include aqueous or nonaqueous solutions, preferably with physiologically compatible buffers or excipients. Such excipients are generally recognized in the field.

[0368] Parenteral injections may involve bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, withAttorney Docket No. 393976-00119

[0369] an added preservative. The pharmaceutical composition described herein may be in a form suitable for parenteral injection as a sterile suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and / or dispersing agents. Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents, which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e g., sterile pyrogen-free water, before use.

[0370] In certain embodiments, delivery systems for pharmaceutical compounds may be employed, such as, for example, liposomes and emulsions. In certain embodiments, compositions provided herein also include an mucoadhesive polymer, selected from among, for example, carboxymethylcellulose, carbomer (acrylic acid polymer), poly (methylmethacryl ate), polyacrylamide, polycarbophil, acrylic acid / butyl acrylate copolymer, sodium alginate and dextran.

[0371] In some embodiments, the compounds described herein may be administered topically and are formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams or ointments. Such pharmaceutical compounds can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.

[0372] The compounds described herein may also be formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG, and the like. In suppository forms of the compositions, a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter is first melted.

[0373] Attorney Docket No. 393976-00119

[0374] In some embodiments, the compounds of Formula (I) disclosed herein are combined with other therapeutic agents, such as other anti-HIV agents, anti-retroviral agents, entry inhibitors, capsid inhibitors, anti-cancer agents, anti-allergic agents, anti-nausea agents (or anti-emetics), pain relievers, cytoprotective agents, and combinations thereof.

[0375] Generally, an agent, such as a compound of Formula (I) disclosed herein, is administered in an amount effective for treating the disease or disorder (i.e., a therapeutically effective amount). Thus, a therapeutically effective amount can be an amount that is capable of at least partially treating, preventing or reversing a disease or disorder. The dose required to obtain an effective amount may vary depending on the agent, formulation, disease or disorder, and individual to whom the agent is administered.

[0376] Determination of effective amounts may also involve in vitro assays in which varying doses of agent are administered to cells in culture and the concentration of agent effective for ameliorating some or all symptoms is determined in order to calculate the concentration required in vivo. Effective amounts may also be based in in vivo animal studies.

[0377] An agent can be administered prior to, concurrently with and subsequent to the appearance of symptoms of a disease or disorder.

[0378] In some embodiments, the compositions described herein are provided as pharmaceutical and / or therapeutic compositions. The pharmaceutical and / or therapeutic compositions of the present disclosure can be administered in a number of ways depending upon whether local or systemic treatment is desired. Administration can be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Compositions and formulations for topical administration can include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional carriers; aqueous, powder, or oily bases; thickeners; and the like can be necessary or desirable. Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders can be desirable. Compositions and formulations for parenteral, intrathecal orAttorney Docket No. 393976-00119

[0379] intraventricular administration can include sterile aqueous solutions that can also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients. Pharmaceutical and / or therapeutic compositions of the present disclosure include, but are not limited to, solutions, emulsions, and liposome containing formulations. These compositions can be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

[0380] The pharmaceutical and / or therapeutic formulations, which can conveniently be presented in unit dosage form, can be prepared according to conventional techniques well known in the pharmaceutical / nutraceutical industries. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product. The compositions of the present disclosure can be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present disclosure can also be formulated as suspensions in aqueous, non-aqueous, oil-based, or mixed media. Suspensions can further contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and / or dextran. The suspension can also contain stabilizers. In one embodiment of the present disclosure the pharmaceutical compositions can be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product.

[0381] The pharmaceutical composition described herein may be in unit dosage forms suitable for single administration of precise dosages. In unit dosage form, the formulation is divided into unit doses containing appropriate quantities of one or more compound. The unit dosage may be in the form of a package containing discrete quantities of the formulation. Non-limiting examples are packaged tablets or capsules, and powders in vials or ampoules. Aqueous suspension compositions can be packaged in single-dose non-reclosable containers. Alternatively, multiple-dose reclosable containers can be used, in which case it is typical to include a preservative in the composition. By way of example only, formulations for parenteral injection may be presented in unit dosage form,Attorney Docket No. 393976-00119

[0382] which include, but are not limited to ampoules, or in multi-dose containers, with an added preservative.

[0383] Dosing and administration regimes are tailored by the clinician, or others skilled in the pharmacological arts, based upon well-known pharmacological and therapeutic considerations including, but not limited to, the desired level of therapeutic effect, and the practical level of therapeutic effect obtainable. Generally, it is advisable to follow well-known pharmacological principles for administrating chemotherapeutic agents or anti-HIV agents (e.g., it is generally advisable not to change dosages by more than 50% at time and no more than every 3-4 agent halflives). For compositions that have relatively little or no dose-related toxicity considerations, and where maximum efficacy is desired, doses in excess of the average required dose are not uncommon. This approach to dosing is commonly referred to as the “maximal dose” strategy. In certain embodiments, the compounds are administered to a subject at a dose of about 0.0001 mg / kg to about 1,000 mg / kg, 0.001 mg / kg to about 700 mg / kg, 0.01 mg / kg to about 500 mg / kg, 0.01 mg / kg to about 200 mg / kg, more preferably at about 0.1 mg / kg to about 100 mg / kg, even more preferably at about 0.5 mg / kg to about 50 mg / kg. When the compounds described herein are co-administered with another agent (e.g., as sensitizing agents), the effective amount may be less than when the agent is used alone. Dosing may be once per day or multiple times per day for one or more consecutive days.

[0384] VI. Method of Treatment

[0385] The present disclosure provides compounds and methods for modulating histone deacetylase (HDAC) activity and / or histone decrotonylation (HDCR) activity of the histone deacetylase 3 enzyme (HDAC3).

[0386] Such inhibition of activity may be assessed and demonstrated by a wide variety of ways generally known in the art. Non-limiting examples include measure induction of histone crotonylation in isolated histone proteins by Western blot. Kits, antibodies, and commercially available assays can be utilized for determining one or more of the above.

[0387] The disclosure provides methods of inhibiting decrotonylation activity of the HDAC3 enzyme, by contacting a cell, tissue, or organ expressing HDAC3 with an effective amount of a compound, prodrug or salt of Formula (I) disclosed herein, wherein the cell, tissue or organ is derived from a an organism, i.e., a patient, having a retroviral infection (e.g., an HIV infection, anAttorney Docket No. 393976-00119

[0388] SIV infection, and / or AIDS). In some embodiments, the patient is a mammal (e.g., a human, nonhuman primates, and humanized mice). In some embodiments, the tissue or organ is brain tissue or bone marrow tissue.

[0389] In some embodiments, the cells used in the methods disclosed herein can be T-cells or non-T cells, e.g. myeloid cells including microglia. In some embodiments, the cells derived from a patient having a retroviral infection (e.g., an HIV-infection and / or AIDS) are selected from the group consisting of CD4+T cells (primary, helper, active and / or resting and / or memory), natural killer T (NKT) cells, Treg cells, and CD8+cells.

[0390] In some embodiments, the cells derived from a patient having a retroviral infection (e.g., an HIV-infection and / or AIDS) are tissue myeloid cells (e.g., macrophages, dendritic cells, neutrophils, basophils, eosinophils, mast cells and microglia). In a particular embodiment, the cells derived from a patient having an HIV-infection and / or AIDS are non-T cells selected from the group consisting of microglia (e.g., brain) and macrophages.

[0391] In such methods, the contacting step occurs in vivo, ex vivo, or in vitro.

[0392] For example, in some embodiments, the disclosure provides methods of inhibiting decrotonylation activity of the HDAC3 enzyme in a cell by contacting the cell with an amount of a compound as disclosed herein sufficient to inhibit its decrotonylation activity. In some embodiments, the disclosure provides methods of inhibiting decrotonylation activity of the HDAC3 enzyme in a tissue by contacting the tissue with an amount of a compound, prodrug or salt of Formula (I) as disclosed herein, sufficient to inhibit the decrotonylation activity of the HDAC3 enzyme in the tissue. In some embodiments, the disclosure provides methods of inhibiting decrotonylation activity of the HDC3 enzyme in an organism (e.g., mammal, human, etc.) by contacting the organism with an amount of a compound, prodrug or salt of Formula (I)) as disclosed herein, sufficient to inhibit the decrotonylation activity of the HDC3 enzyme in the organism.

[0393] The disclosure provides methods for treating a disease (e.g., cancer, a retroviral infection such as HIV and / or AIDS, and the acute kidney disease) by administering a compound, prodrug, or salt of Formula (I) disclosed herein, to a subject suffering from the disease, wherein the compound binds to a HDAC3 enzyme and / or inhibits (HDAC) activity and / or inhibits HDCR activity. In such embodiments, the compound, prodrug, or salt of Formula (I) disclosed hereinAttorney Docket No. 393976-00119

[0394] selectively inhibits HDCR activity. Selectivity of HDCR activity over HDAC activity can be determined using standard methods known in the art, e g., Western blotting techniques.

[0395] For the above methods, inhibition of HDCR activity and / or reversing or re-activating HIV latency in a cell can be assessed by measuring changes in cellular crotonylation levels and / or changes in viral transcription, i.e., HIV transcription.

[0396] In some embodiments, the above methods will exhibit a decrease in decrotonylation, which can vary. In some embodiments, the above methods exhibit a decrease in decrotonylation of at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or by about 100% compared to control. In addition, or in the alternative, the above methods exhibit a decrease in decrotonylation of less than about 100%, less than about 95%, less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 1%, or less than 0.5% compared to control.

[0397] In some embodiments, the above methods exhibit an increase in HIV transcription, which can vary. For instance, in some embodiments, the compounds used in the above methods exhibit an increase in retroviral transcription (e g., HIV transcription) of at least about 0.5 fold, at least about 1-fold, at least about 1.5-fold, at least about 2.0-fold, at least about 2.5 fold, at least about 3.0 fold, at least about 3.5 fold, at least about 4.0 fold, at least about 4.5 fold, at least about 5.0 fold, at least about 5.5 fold, at least about 6.0 fold, at least about 6.5 fold, at least about 7.0 fold, at least about 7.5 fold, at least about 8.0 fold, at least about 8.5 fold, at least about 9.0 fold, at least about 9.5 fold or at least about 10.0 fold compared to control. In addition, or in the alternative, the compounds disclosed herein employed in the above methods exhibit an increase of retroviral transcription (e.g., HIV transcription) at less than about 10-fold, less than about 9.5-fold, less than about 9.0-fold, less than about 8.5-fold, less than about 8.0 fold, less than about 7.5-fold, less than about 7.0-fold, less than about 6.5-fold, less than about 6.0-fold, less than about 5.5-fold, less than about 5.0-fold, less than about 4.5-fold, less than about 4.0-fold, less than about 3.5-fold, less thanAttorney Docket No. 393976-00119

[0398] about 3.0-fold, less than about 2.5-fold, less than about 2.0-fold, less than about 1.5-fold, less than about 1.0-fold, or less than about 0.5-fold compared to control.

[0399] In some embodiments, the disclosure provides a method of treating a subject having an HIV infection comprising administering a therapeutically effective amount of a compound, prodrug or salt described herein, for example, a compound, prodrug or salt of Formula (I) disclosed herein, to the subject. The method is effective for targeting any HIV infection (e.g., HIV-1, HIV-2 and any circulating recombinant form thereof) including latent HIV infection. In some embodiments, the method is effective for targeting and / or treating one or more HIV-1 subtypes selected from the group consisting of subtype A, subtype B, subtype C, subtype D, subtype F, subtype G, subtype H, subtype J, and subtype K. In a specific embodiment, the method is effective for targeting latent HIV.

[0400] In some embodiments, the disclosure provides a method treating latent HIV in a subject by reversing HIV latency and / or reactivating latent HIV via the administration of a therapeutically effective amount of a compound, prodrug or pharmaceutically acceptable salt of Formula (I) as disclosed herein.

[0401] In some embodiments, the disclosure provides methods of treating a subject having an HIV infection with a compound as disclosed herein for delaying the onset of AIDS comprising administering a therapeutically effective amount of a compound, prodrug or salt of Formula (I) as described herein. AIDS as referred to herein is when the HIV-infected subject has a drop in CD4 count to less than 200 cells / mm3 or has acquired any opportunistic infections or cancers often associated with AIDS (i.e., AIDS defining conditions). Exemplary opportunistic infections associated with AIDS include, but are not limited to, candidiasis, Toxoplasma gondii Encephalitis, Vulvovaginal Candidiasis Salmonella infection, toxoplasmosis, pneumonia, and tuberculosis (TB). Exemplary cancers associated with AIDS include, but are not limited to, Kaposi sarcoma, Non-Hodgkin's lymphoma, cervical cancer, anal cancer, lung cancer, liver cancer and brain lymphoma.

[0402] In some embodiments, the disclosure provides methods for treating an HIV infection in a subject comprising administering a therapeutically effective amount of a compound, prodrug or salt of Formula (I) disclosed herein in combination with a therapeutically effective amount of one or more additional therapeutic agents which are suitable for treating an HIV infection and / or AIDS. In such embodiments, the additional therapeutic agent may be an anti-HIV agent. For example, inAttorney Docket No. 393976-00119

[0403] some embodiments, the additional therapeutic agent is selected from the group consisting of HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors (e.g., CCR5 inhibitors, gp41 inhibitors (i.e., fusion inhibitors) and CD4 attachment inhibitors), CXCR4 inhibitors, gpl20 inhibitors, G6PD and NADH-oxidase inhibitors, HIV vaccines, HIV maturation inhibitors, latency reversing agents (e.g., histone deacetylase inhibitors, proteasome inhibitors, protein kinase C (PKC) activators, and BRD4 inhibitors), compounds that target the HIV capsid (“capsid inhibitors”; e.g., capsid polymerization inhibitors or capsid disrupting compounds, HIV nucleocapsid p7 (NCp7) inhibitors, HIV p24 capsid protein inhibitors), pharmacokinetic enhancers, immune-based therapies (e.g., Pd-1 modulators, Pd-Ll modulators, toll like receptors modulators, IL- 15 agonists), HIV antibodies, bispecific antibodies and “antibody -like” therapeutic proteins (e.g., DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs®, Fab derivatives) including those targeting HIV gpl20 or gp41, combination drugs for HIV, HIV pl7 matrix protein inhibitors, IL-13 antagonists, Peptidyl -prolyl cis-trans isomerase A modulators, Protein disulfide isomerase inhibitors, Complement C5a receptor antagonists, DNA methyltransferase inhibitor, HIV vif gene modulators, HIV-1 viral infectivity factor inhibitors, TAT protein inhibitors, HIV-1 Nef modulators, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, Rev protein inhibitors, Integrin antagonists, Nucleoprotein inhibitors, Splicing factor modulators, COMM domain containing protein 1 modulators, HIV Ribonuclease H inhibitors, Retrocyclin modulators, CDK-9 inhibitors, Dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, Ubiquitin ligase inhibitors, Deoxycytidine kinase inhibitors, Cyclin dependent kinase inhibitors Proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, PI3K inhibitors, compounds such as those disclosed in WO 2013 / 006738 (Gilead Sciences), US 2013 / 0165489 (University of Pennsylvania), WO 2013 / 091096A1 (Boehringer Ingelheim), WO 2009 / 062285 (Boehringer Ingelheim), US20140221380 (Japan Tobacco), US20140221378 (Japan Tobacco), WO 2010 / 130034 (Boehringer Ingelheim), WO 2013 / 159064 (Gilead Sciences), WO 2012 / 145728 (Gilead Sciences), W02012 / 003497 (Gilead Sciences), W02014 / 100323 (Gilead Sciences), WO2012 / 145728 (Gilead Sciences), WO2013 / 159064 (Gilead Sciences) and WO 2012 / 003498Attorney Docket No. 393976-00119

[0404] (Gilead Sciences) and WO 2013 / 006792 (Pharma Resources), and other drugs for treating HIV, and combinations thereof. In certain embodiments, the additional therapeutic is selected from the group consisting of HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, pharmacokinetic enhancers, and combinations thereof.

[0405] In some embodiments, the therapeutic agent is a combination drug selected from the group consisting of ATRIPLA® (efavirenz+tenofovir disoproxil fumarate+emtricitabine), COMPLERA® (EVIPLERA®, rilpivirine+tenofovir disoproxil fumarate+emtricitabine), STRIBILD® (elvitegravir+cobicistat+tenofovir disoproxil fumarate+emtricitabine), dolutegravir+abacavir sulfate+lamivudine, dolutegravir+abacavir sulfate+lamivudine, lamivudine+nevirapine+zidovudine, dolutegravir+rilpivirine, atazanavir sulfate+cobicistat, darunavir+cobicistat, efavirenz+lamivudine+tenofovir disoproxil fumarate, tenofovir alafenamide hemifumarate+emtricitabine+cobicistat+elvitegravir, Vacc-4x+romidepsin, darunavir+tenofovir alafenamide hemifumarate+emtricitabine+cobicistat, APH-0812, raltegravir+lamivudine, KALETRA® (ALUVIA®, lopinavir+ritonavir), atazanavir sulfate+ritonavir, COMBIVIR® (zidovudine+lamivudine, AZT+3TC), EPZICOM® (Livexa®, abacavir sulfate+lamivudine, ABC+3TC), TRIZIVIR® (abacavir sulfate+zidovudine+lamivudine, ABC+AZT+3TC), TRUVADA® (tenofovir disoproxil fumarate+emtricitabine, TDF+FTC), tenofovir+lamivudine and lamivudine+tenofovir disoproxil fumarate; and / or

[0406] HIV protease inhibitors selected from the group consisting of amprenavir, atazanavir, fosamprenavir, fosamprenavir calcium, indinavir, indinavir sulfate, lopinavir, ritonavir, nelfinavir, nelfinavir mesylate, saquinavir, saquinavir mesylate, tipranavir, brecanavir, darunavir, DG-17, TMB-657 (PPL- 100) and TMC-310911; and / or

[0407] HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase selected from the group consisting of delavirdine, delavirdine mesylate, nevirapine, etravirine, dapivirine, doravirine, rilpivirine, efavirenz, KM-023, VM-1500, lentinan and AIC-292; and / or

[0408] HIV nucleoside or nucleotide inhibitors of reverse transcriptase selected from the group consisting of VIDEX® and VIDEX® EC (didanosine, ddl), zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, censavudine, abacavir, abacavir sulfate, amdoxovir, elvucitabine, alovudine, phosphazid, fozivudine tidoxil, apricitabine, amdoxovir, KP-1461,

[0409] Attorney Docket No. 393976-00119

[0410] fosalvudine tidoxil, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir alafenamide, tenofovir alafenamide hemifumarate, tenofovir alafenamide fumarate, adefovir, adefovir dipivoxil, and festinavir; and / or HIV integrase inhibitors selected from the group consisting of curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, raltegravir, elvitegravir, dolutegravir andcabotegravir; and / or

[0411] HIV non-catalytic site, or allosteric, integrase inhibitors (NCINI) selected from the group consisting of CX-05168, CX-05045 and CX-14442; and / or

[0412] HIV gp41 inhibitors selected from the group consisting of enfuvirtide, sifuvirtide and albuvirtide; and / or

[0413] HIV entry inhibitors selected from the group consisting of cenicriviroc; and / or

[0414] HIV gpl20 inhibitors selected from the group consisting of Radha-108 (Receptol) and BMS-663068; and / or

[0415] CCR5 inhibitors selected from the group consisting of aplaviroc, vicriviroc, maraviroc, cenicriviroc, PRO-140, Adaptavir (RAP-101), TBR-220 (TAK-220) and vMIP (Haimipu); and / or CD4 attachment inhibitors selected from the group consisting of ibalizumab; and / or CXCR4 inhibitors selected from the group consisting of plerixafor, ALT- 1188, vMIP and

[0416] Haimipu; and / or

[0417] Pharmacokinetic enhancers selected from the group consisting of cobicistat and ritonavir; and / or

[0418] Immune-based therapies selected from the group consisting of derma Vir, interleukin-7, lexgenleucel-T (VRX-496), plaquenil (hydroxychloroquine), proleukin (aldesleukin, IL-2), interferon alfa, interferon alfa-2b, interferon alfa-n3, pegylated interferon alfa, interferon gamma, hydroxyurea, mycophenolate mofetil (MPA) and its ester derivative mycophenolate mofetil (MMF), WF-10, ribavirin, IL-2, IL-2 XL, IL-12, polymer polyethyleneimine (PEI), Gepon, VGV-1, MOR-22, BMS-936559, toll-like receptors modulators (tlrl, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlrlO, tlrl 1, tlrl 2 and tlrl 3), rintatolimod and IR-103; and / or

[0419] HIV vaccines selected from the group consisting of peptide vaccines, recombinant subunit protein vaccines, live vector vaccines, DNA vaccines, virus-like particle vaccines (pseudovirionAttorney Docket No. 393976-00119

[0420] vaccine), CD4-derived peptide vaccines, vaccine combinations, rgpl20 (AIDSVAX), ALVAC HIV (vCP1521) / AIDSVAX B / E (gpl20) (RV144), Remune, ITV-1, Contre Vir, Ad5-ENVA-48, DCVax-001 (CDX-2401), PEP-6409, Vacc-4x, Vacc-C5, VAC-3S, multiclade DNA recombinant adenovirus-5 (rAd5), Pennvax-G, VRC-HIVMAB060-00-AB, AVX-101, Tat Oyi vaccine, AVX-201, HIV-LAMP-vax, Ad35, Ad35-GRIN, NAcGM3 / VSSP ISA-51, poly-ICLC adjuvanted vaccines, Tatlmmune, GTU-multiHIV (FIT-06), AGS-004, gp!40[delta]V2. TVl+MF-59, rVSVIN HIV-1 gag vaccine, SeV-Gag vaccine, AT-20, DNK-4, Ad35-GRIN / ENV, TBC-M4, HIVAX, HIVAX-2, NYVAC-HIV-PT1, NYVAC-HIV-PT4, DNA-HIV-PT123, Vichrepol, rAAVl-PG9DP, GOVX-B11, GOVX-B21, ThV-01, TUTI-16, VGX-3300, TVI-HIV-1, Ad-4 (Ad4-env Clade C+Ad4-mGag), EN41-UGR7C, EN41-FPA2, PreVaxTat, TL-01, SAV-001, AE-H, MYM-V101, CombiHIVvac, AD VAX, MYM-V201, MVA-CMDR and DNA-Ad5 gag / pol / nef / nev (HVTN505); and / or

[0421] HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins (such as DARTs®, Duobodies®, Bites®, XmAbs®, TandAbs®, Fab derivatives) including BMS-936559, TMB-360 and those targeting HIV gpl20 or gp41 selected from the group consisting of bavituximab, UB-421, C2F5, C2G12, C4E10, C2F5+C2G12+C4E10, 3-BNC-117, KD-247, PGT145, PGT121, MDX010 (ipilimumab), VRC01, A32, 7B2, 10E8 and VRC07; and / or

[0422] Latency reversing agents selected from the group consisting of Histone deacetylase inhibitors such as Romidepsin, vorinostat (or SAHA), panobinostat; Proteasome inhibitors such as Velcade; protein kinase C (PKC) / NF-KB activators such as Indolactam, Prostratin, Ingenol B, PEP005, and DAG-lactones, lonomycin, PMA, noncanonical NF-KB activators (i.e. Smac mimetics or IAP inhibitors) such as AZD5582 and Birinapant, GSK-343, BRD2 and BRD4 inhibitors such as JQ1 and OTX-015, IL-15, disulfram, and amphotericin B; and / or

[0423] HIV nucleocapsid p7 (NCp7) inhibitors selected from the group consisting of azodicarbonamide; and / or

[0424] HIV maturation inhibitors selected from the group consisting of BMS-955176 and GSK-2838232; and / or

[0425] PI3K inhibitors selected from the group consisting of idelalisib, AZD-8186, buparlisib, CLR-457, pictilisib, neratinib, rigosertib, rigosertib sodium, EN-3342, TGR-1202, alpelisib, duvelisib, UCB-5857, taselisib, XL-765, gedatolisib, VS-5584, copanlisib, CAI orotate, perifosine, RG-7666, GSK-2636771, DS-7423, panulisib, GSK-2269557, GSK-2126458, CUDC-Attorney Docket No. 393976-00119

[0426] 907, PQR-309, INCB-040093, pilaralisib, BAY-1082439, puquitinib mesylate, SAR-245409, AMG-319, RP-6530, ZSTK-474, MLN-1117, SF-1126, RV-1729, sonolisib, LY-3023414, SAR-260301 and CLR-1401; and / or

[0427] other drugs for treating HIV selected from the group consisting of TR-452, MK-8591, REP 9, CYT-107, alisporivir, NOV-205, IND-02, metenkefalin, PGN-007, Acemannan, Gamimune, SCY-635, Prolastin, 1,5-dicaffeoylquinic acid, BIT-225, RPI-MN, VSSP, Hlviral, IMO-3100, SB-728-T, RPI-MN, VIR-576, HGTV-43, MK-1376, rHIV7-shl-TAR-CCR5RZ, MazF gene therapy, BlockAide and PA-1050040 (PA-040).

[0428] In some embodiments, the therapeutic agent is an anti-retroviral agent including any agents that are routinely used in HAART therapy. Examples of anti-retroviral agents include reverse transcriptase inhibitors (e.g., nucleoside / nucleotide reverse transcriptase inhibitors, such as zidovudine, emtricitibine, lamivudine and tenofivir; and non-nucleoside reverse transcriptase inhibitors (e.g., efavarenz, nevirapine, rilpivirine); protease inhibitors (e.g., tipiravir, darunavir, indinavir); entry inhibitors (e.g., maraviroc); fusion inhibitors (e.g., enfuviritide); or integrase inhibitors (e.g., raltegrivir, dolutegravir). Anti-retroviral agents can also include multi-class combination agents for example, combinations of emtricitabine, efavarenz, and tenofivir; combinations of emtricitabine; rilpivirine, and tenofivir; or combinations of elvitegravir, cobicistat, emtricitabine and tenofivir.

[0429] The subject in any of the above-described methods is a subject that has been diagnosed with HIV infection and / or AIDS. In some embodiments, the subject may be resistant to one or more of commercially available drugs used for the treatment of HIV infection and / or AIDS, e.g., drugs used in antiretroviral therapy (ART).

[0430] In some embodiments, the subject or patient in any of the above-described methods include, but not limited to, rodents and mammals, e.g., humans and / or non-human primate (i.e., rhesus macaques).

[0431] In some embodiments, the compounds employed in any of the above-described methods can covalently or non-covalently bind to HDAC3. In such embodiments, these compounds bind (covalently or noncovalently) to the enzyme in a regions that is outside of the zinc-binding pocket of HDAC3. In some embodiments, the compounds disclosed herein bind (covalently or noncovalently) with amino acid residues D57, QI 33, R265 and R301 of HDAC3 all located outside of the enzyme’s zinc-binding pocket. In such instances, the compounds disclosed hereinAttorney Docket No. 393976-00119

[0432] elicit a structural change (e.g., changes in the three-dimensional shape of the enzyme) of the HDAC3 enzyme thereby altering the zinc-binding pocket.

[0433] In some embodiments, the disclosure provides a method for treating cancer in a subject, comprising administering a compound, prodrug or salt described herein, for example, a compound, prodrug or salt of Formula (I) disclosed herein, to the subject. In some embodiments, the cancer is mediated by a histone deacetylase (HDAC) expression (e.g., aberrant expression, overexpression, etc.) and / or activity. In some embodiments, the cancer is mediated by elevated levels of histone crotonylation. In some embodiments, the compound, prodrug or salt of Formula (I) is a selective HDAC inhibitor as described herein. In some embodiments, the compound, prodrug or salt of Formula (I) is a selective HDCR inhibitor as disclosed herein. In some embodiments, the compound, prodrug or salt of Formula (I) is a dual inhibitor, i.e., a non-selective HDAC / HDCR inhibitor as disclosed herein.

[0434] In some embodiments, the method relates to the treatment of cancer such as acute myeloid leukemia, cancer in adolescents, adrenocortical carcinoma childhood, AIDS-related cancers, e.g., Lymphoma and Kaposi's Sarcoma, anal cancer, appendix cancer, astrocytomas, atypical teratoid, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, bronchial tumors, burkitt lymphoma, carcinoid tumor, atypical teratoid, embryonal tumors, germ cell tumor, primary lymphoma, cervical cancer, childhood cancers, chordoma, cardiac tumors, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), chronic myleoproliferative disorders, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, extrahepatic ductal carcinoma in situ (DCIS), embryonal tumors, CNS cancer, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, ewing sarcoma, extracranial germ cell tumor, extragonadal germ cell tumor, eye cancer, fibrous histiocytoma of bone, gall bladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumors (GIST), germ cell tumor, gestational trophoblastic tumor, hairy cell leukemia, head and neck cancer, heart cancer, liver cancer, hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors, pancreatic neuroendocrine tumors, kidney cancer, laryngeal cancer, lip and oral cavity cancer, liver cancer, lobular carcinoma in situ (LCIS), lung cancer, lymphoma, metastatic squamous neck cancer with occult primary, midline tract carcinoma, mouth cancer multiple endocrine neoplasia syndromes, multiple myeloma / plasma cell neoplasm, mycosis fungoides, myelodysplastic syndromes,

[0435] Attorney Docket No. 393976-00119

[0436] myelodysplastic / myeloproliferative neoplasms, multiple myeloma, merkel cell carcinoma, malignant mesothelioma, malignant fibrous histiocytoma of bone and osteosarcoma, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-hodgkin lymphoma, nonsmall cell lung cancer (NSCLC), oral cancer, lip and oral cavity cancer, oropharyngeal cancer, ovarian cancer, pancreatic cancer, papillomatosis, paraganglioma, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pleuropulmonary blastoma, primary central nervous system (CNS) lymphoma, prostate cancer, rectal cancer, transitional cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, stomach (gastric) cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, T-Cell lymphoma, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter, trophoblastic tumor, unusual cancers of childhood, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, or Viral-Induced cancer. In some embodiments, the method relates to the treatment of a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin, e.g., psoriasis, restenosis, or prostate, e.g., benign prostatic hypertrophy (BPH). In some cases, the method relates to the treatment of leukemia, hematologic malignancy, solid tumor cancer, prostate cancer, e g., castration-resistant prostate cancer, breast cancer, Ewing's sarcoma, bone sarcoma, primary bone sarcoma, T-cell prolymphocyte leukemia, glioma, glioblastoma, liver cancer, e.g., hepatocellular carcinoma, or diabetes.

[0437] In some embodiments, the compounds of Formula (I) in the above methods disclosed herein are combined with other therapeutic agents, such as other anti-cancer agents, anti-allergic agents, anti-nausea agents (or anti-emetics), pain relievers, cytoprotective agents, and combinations thereof. In another embodiment, the compounds of Formula (I) disclosed herein are combined with another therapeutic agent capable of inhibiting BRAF, MEK, CDK4 / 6, SHP-2, HD AC, EGFR, MET, mTOR, PI3K or AKT, or a combination thereof. Such exemplary therapeutic agents include, but are note limited to, ABVD, AC, Abemaciclib (Verzenois), Abiraterone (Zytiga), Abraxane, Abstral, Acalabrutinib, Actimorph, Actinomycin D, Actiq, Adriamycin, Afatinib (Giotrif), Afinitor, Aflibercept, and folinic acid, fluorouracil and irinotecan (FOLFIRI), Aldara, Alectinib (Alecensa), Alkeran, Alpelisib and fulvestrant, Anastrazole (Arimidex), Apalutamide, Ara C, Arimidex, Aromasin, Arsenic trioxide and Tretinoin, Asciminib, Asparaginase (Spectrila, Erwinase, Oncaspar), Atezolizumab (Tecentriq), Atezolizumab and bevacizumab, Atezolizumab and nab-paclitaxel, Avelumab, Axitinib (Inlyta), Azacitidine

[0438] Attorney Docket No. 393976-00119

[0439] (Vidaza), Azacitidine tablets (Onureg), BEACOPDac, BEACOPP, BEAM, Belzutifan (Welireg), Bendamustine (Levact), Besponsa, Bevacizumab (Avastin), Bexarotene (Targretin), Bicalutamide (Casodex), Bleomycin, etoposide and platinum (BEP), Blinatumomab (Blincyto), Bortezomib (Velcade), cyclophosphamide and dexamethasone (VCD), Bosutinib (Bosulif), Brentuximab, Brigatinib (Alunbrig), Buserelin (Suprefact), Busulfan, CAPE-OX, CAPOX, CAPTEM, CAV chemotherapy, CCNU, CHOP chemotherapy drugs, CPX351, Cabazitaxel (Jevtana), Cabometyx, Cabozantinib capsules (Cometriq), Cabozantinib tablets (Cabometyx), Caelyx, Campto, Capecitabine, Capecitabine and temozolomide (CAPTEM), CarboTaxol, Carboplatin, Carboplatin and etoposide, Carboplatin and paclitaxel, Carfilzomib and dexamethasone, Carmustine (BCNU), Casodex, Cemiplimab, Ceritinib (Zykadia), Cetuximab (Erbitux), Chlorambucil (Leukeran), Cisplatin, Cisplatin and capecitabine (CX), Cisplatin and fluorouracil (5FU), Cisplatin, etoposide and ifosfamide (VIP), Cisplatin, fluorouracil (5FU) and trastuzumab, Cladribine, Columvi, Cometriq, Crizotinib (Xalkori), Cyclophosphamide, Cyclophosphamide, thalidomide and dexamethasone (CTD), Cyprostat, Cyproterone acetate, Cytarabine (Ara C, cytosine arabinoside), Cytarabine into spinal fluid (intrathecal cytarabine), Cytosine arabinoside, DA, DHAP, DTIC, Dabrafenib (Tafinlar), Dabrafenib and trametinib, Dacarbazine (DTIC), Dacomitinib, Dactinomycin (actinomycin D), Daratumumab, Daratumumab, bortezomib, thalidomide and dexamethasone (DVTD), Daratumumab, lenalidomide and dexamethasone (DRD), Darolutamide (Nubeqa), Darzalex, Dasatinib, Daunorubicin and cytarabine (DA), Daunorubicin, cytarabine and midostaurin, Decapeptyl SR (breast cancer), Decapeptyl SR (prostate cancer), Degarelix (Firmagon), Denosumab injection, Dexamethasone, Diamorphine, Docetaxel (Taxotere), Docetaxel, cisplatin and fluorouracil (TPF), Dostarlimab, Doxifos, Doxorubicin, Doxorubicin and ifosfamide, Durogesic, Durvalumab (Imfinzi), EC, ECF, EOX, EP (Etoposide and cisplatin), ESHAP, Effentora, Encorafenib and binimetinib, Encorafenib and cetuximab, Entrectinib (Rozlytrek), Enzalutamide, Epcoritamab (Tepkinly), Epirubicin, Epirubicin, cisplatin and capecitabine (ECX), Epirubicin, oxaliplatin and fluorouracil (EOF), Erbitux, Eribulin (Halaven), Erlotinib (Tarceva), Erwinase, Etopophos, Etoposide (Etopophos), Everolimus (Afmitor), Exemestane (Aromasin), FLAG, FLAG-Ida, FOLFIRINOX, FOLFOX, FOLFOXIRI, Faslodex, Femara, Fentanyl, Firmagon, Fludarabine (Fludara), Fludarabine, cyclophosphamide and rituximab (FCR), Fluorouracil (5FU), Fluorouracil (5FU) and mitomycin C, Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel (FLOT), Flutamide, Folinic acid, fluorouracil and

[0440] Attorney Docket No. 393976-00119

[0441] irinotecan (FOLFIRI), Fotivda, Fulvestrant (faslodex), Futibatinib (Lytgobi), G-CSF, GDP, Gefitinib (Iressa), GemCarbo (gemcitabine and carboplatin), GemTaxol, Gemcitabine, Gemcitabine and capecitabine (GemCap), Gemcitabine and cisplatin (GC), Gemcitabine and nab-paclitaxel, Gemcitabine and paclitaxel (GemTaxol), Gemtuzumab ozogamicin, daunorubicin and cytarabine, Gemzar, Gilteritinib (Xospata), Giotrif, Gliadel (carmustine wafers), Glivec, Glofitamab (Columvi), Gonapeptyl Depot, Goserelin (Zoladex) for breast cancer, Goserelin for prostate cancer, Granulocyte colony stimulating factor (G-CSF), Halaven, Herceptin, Herzuma, Hycamtin, Hydrea, Hydrocortisone, Hydroxycarbamide (Hydrea), Hydroxyurea, ICE, IPE, Ibandronic acid (Bondronat), Ibrance, Ibrutinib (Imbruvica), Iclusig, Idarubicin, Ifosfamide, Imatinib (Glivec), Imiquimod cream (Aldara), Inotuzumab ozogamicin, Ipilimumab (Yervoy), Ipilimumab and nivolumab, IrCap, Iressa, Irinotecan (Campto), Irinotecan and capecitabine (Xeliri), Irinotecan de Gramont, Irinotecan modified de Gramont, Ivosidenib (Tibsovo), Ivosidenib and azacitidine, Ixazomib, lenalidomide and dexamethasone, Jevtana, Kadcyla, Keytruda, Kimmtrak, Kisqali, L-DA, Lanreotide (Somatuline), Larotrectinib (Vitrakvi), Lenalidomide (Revlimid), Lenvatinib, Letrozole (Femara), Leukeran, Leuprorelin, Leustat, Levact, Liposomal daunorubicin and cytarabine (Vyxeos, CPX351, L-DA), Litak, Lomustine, Loncastuximab tesirine (Zynlonta), Lonsurf, Lorlatinib (Lorviqua), Lutrate, Lynparza, Lysodren, Lytgobi, MAP, MMM, MST Continus, MV AC, MXL, Mabthera, Medroxyprogesterone acetate (Provera), Megace, Megestrol acetate (Megace), Melphalan, Mepact, Mercaptopurine, Methotrexate, cytarabine, thiotepa and rituximab (MATRix), Methylprednisolone, Midostaurin (Rydapt), Mifamurtide, Mitomycin C, Mitotane (Lysodren), Mitoxana, Mitoxantrone (Mitozantrone), Mobocertinib (Exkivity), Modified de Gramont, Morphgesic SR, Morphine, Nab paclitaxel (Abraxane), Navelbine, Nelarabine (Atriance), Neratinib (Nerlynx), Nerlynx, Nexavar, Nilotinib (Tasigna), Nintedanib, Nipent, Niraparib (Zejula), Nivolumab (Opdivo), Nivolumab and relatlimab (Opdualag), Obinutuzumab (Gazyvaro), Octreotide, Olaparib (Lynparza), Ontruzant, Onureg, Opdivo, Opdualag, Oramorph, Orgovyx, Osimertinib (Tagrisso), OxCap, Oxaliplatin, Oxaliplatin and capecitabine (XELOX, CAPOX), PC, PE, Paclitaxel (Taxol), Paclitaxel and carboplatin (PC, CarboTaxol), Palbociclib (Ibrance), Pamidronate disodium, Panitumumab (Vectibix), Panobinostat, bortezomib and dexamethasone, Pazopanib (Votrient), Peginterferon alfa 2a, Pegylated liposomal doxorubicin, Pembrolizumab (Keytruda), Pemetrexed (Alimta), Pemetrexed and carboplatin, Pemetrexed and cisplatin, Pemigatinib, Pentostatin (Nipent), Perjeta, PertuzumabAttorney Docket No. 393976-00119

[0442] (Peqeta), Phesgo or trastuzumab and pertuzumab, Polatuzumab vedotin, bendamustine and rituximab (Pola-BR), Pomalidomide and dexamethasone, Ponatinib, Prednisolone, Procarbazine, Procarbazine, lomustine and vincristine (PCV), Prolia, Prostap, Provera, R-CHOP, R-CVP, R-DHAP, R-ESHAP, R-GCVP, R-GDP, R-Idelalisib (Zydelig), RICE, Raloxifene, Raltitrexed (Tomudex), Regorafenib (Stivarga), Relugolix (Orgovyx), Revlimid, Ribociclib (Kisqali), Risedronate sodium, Rituximab, Rixathon, Rubraca, Rucaparib (Rubraca), Ruxience, Ruxolitinib, Sacituzumab govitecan (Trodelvy), Selpercatinib, Sevredol, Sodium clodronate (Loron), Sorafenib, Sotorasib (Lumykras), Steroids (dexamethasone, prednisolone, methylprednisolone and hydrocortisone), Stivarga, Streptozocin (Zanosar), Sunitinib (Sutent), TC protocol, TIP, Tafinlar, Tagrisso, Talazoparib (Talzeena), Talimogene laherparepvec (T-VEC), Tamoxifen, Tarceva, Targretin, Tasigna, Taxol, Taxotere, Tebentafusp (Kimmtrak), Tecentriq, Teclistamab, Temodal, Temozolomide (Temodal), Tepadina, Tepotinib, Thiotepa, Tivozanib (Fotivda), Tomudex, Topotecan (Hycamtin), Trabectedin (Yondelis), Trastuzumab (Herceptin), Trastuzumab and pertuzumab, Trastuzumab deruxtecan, Trastuzumab emtansine (Kadcyla), Treosulfan, Trifluridine and tipiracil (Lonsurf), Triptorelin (Decapeptyl SR or Gonapeptyl), Truxima, Tucatinib, trastuzumab and capecitabine, VDC / IE, Vargatef, VelP, Vectibix, Velcade, Vemurafenib (Zelboraf), Venetoclax (Venclyxto), Venetoclax and azacitidine, Venetoclax and low dose cytarabine, Vidaza, Vinblastine, Vincristine, Vinorelbine (Navelbine), Vitrakvi, Votrient, Vyxeos, Welireg, XELOX, Xalkori, Xeloda, Xgeva, Xospata, Xtandi, Yervoy, Yondelis, Zanosar, Zanubrutinib (Brukinsa), Zelboraf, Zoladex, Zoledronic acid (Zometa), Zometa, Zomorph, Zydelig, Zynlonta, and / or Zytiga.

[0443] Co-administration of two or more therapeutic agents refers to the administration of the agents at the same time, at different times such that the time period of their therapeutic effect overlaps, or by the same route. Administration can be simultaneous or sequential, including on different days or weeks.

[0444] In some embodiments, the methods disclosed herein comprise administration of the compounds disclosed herein for prophylactic treatment purposes. In prophylactic applications, compositions containing the compounds or salts thereof described herein are administered to a patient susceptible to or otherwise at risk of a particular disease, disorder or condition (e.g., cancer, HIV and / or AIDS). Such an amount is defined to be a “prophylactically effective amount or dose.” In this use, the precise amounts also depend on the patient's state of health, weight, and the like.

[0445] Attorney Docket No. 393976-00119

[0446] When used in a patient, effective amounts for this use will depend on the severity and course of the disease, disorder or condition, previous therapy, the patient's health status and response to the drugs, and the judgment of the treating clinician. In some embodiments, the compounds disclosed herein can be used in the prophylactic treatment of an HIV infection, AIDS, and / or to delay the onset of AIDS.

[0447] The amount of a given agent that will correspond to such an amount will vary depending upon factors such as the particular compound, disease and its severity, the identity (e.g., weight) of the subject or host in need of treatment, but can nevertheless be determined in a manner recognized in the field according to the particular circumstances surrounding the case, including, e.g., the specific agent being administered, the route of administration, the condition being treated, and the subject or host being treated. In general, however, doses employed for adult human treatment will typically be in the range of about 0.02-about 5000 mg per day, in some embodiments, about 1-about 1500 mg per day. The desired dose may conveniently be presented in a single dose or as divided doses administered simultaneously (or over a short period of time) or at appropriate intervals, for example as two, three, four or more sub-doses per day.

[0448] Toxicity and therapeutic efficacy of such therapeutic regimens can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, the determination of the LD50(the dose lethal to 50% of the population) and the ED50(the dose therapeutically effective in 50% of the population). The dose ratio between the toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD50and ED50. Compounds exhibiting high therapeutic indices are preferred. The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with minimal toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.

[0449] EXAMPLES

[0450] Example 1: Primary resting CD4+T cell isolation and culture

[0451] Leukocytes were obtained from eight individuals with HIV on ART for at least 3 years, all with undetectable HIV RNA in plasma (Table 1). Resting CD4+T cells were isolated using a custom resting CD4+(rCD4+) T cell isolation kit (StemCell Technologies) and cultured in RPMIAttorney Docket No. 393976-00119

[0452] RIO (10% FBS (Avantor), 1 % Penicillin Streptomycin (Gibco), 10 mM HEPES (Gibco), 2 mM L-Glutamine (Gibco), and 1 mM Sodium Pyruvate (Gibco), supplemented with 40 U / mL IL-2 (PeproTech)). All participants were provided with informed consent, and the study was approved by the UNC Chapel Hill Institutional Review Board (IRB).

[0453] Table 1. Characteristics of HIV-positive participant on ART

[0454] A ■ ■ ■ pVL CD4 counts

[0455] PID Gender Ag

[0456] ae Ethnic orig

[0457] ain,.,l x, „,., ART (copies / mL) (cells / pL)

[0458] i— BlaCk / AftiCan n i x

[0459] 51401288 F 59. <20 1365 Biktarvy

[0460] American3

[0461] 50401237 M 43 Hispanic <20 686 Descovy,rTivicay

[0462] 53800546 M 63 White <20 622 Delstrigo

[0463] 46801104 M 27 White 30 977 Biktarvy

[0464] 48301236 M 41 Black / Afncan <2Q 773 Biktarvy

[0465] American3

[0466] 54701180 M 29 Black / Afncan <2o626Biktarvy

[0467] American3

[0468] 51401228 F 44 Black / Afncan <20 1365Biktarvy

[0469] American3

[0470] 51501289 F 40 White <40 1166 Biktarvy

[0471] M, male; F, female; pVL, plasma viral load; ART, antiretroviral therapy.

[0472] Example 2: Last Gift rapid research autopsy program

[0473] Four participants with HIV (LG21, LG29, LG33, and LG34) included in this study were enrolled from the Last Gift rapid research autopsy program, which recruits altruistic PWH with a terminal illness who are well-suppressed on ART for close perimortem follow-up (Table 2). The inclusion criteria for this study were: confirmed HIV diagnosis, a life expectancy of less than six months, ongoing suppressive ART, and no history of central nervous system (CNS) malignancy or immune checkpoint inhibitor chemotherapy. The rapid autopsy tissues were shipped overnightAttorney Docket No. 393976-00119

[0474] to the UNC lab in medium containing antibiotics and ART for isolation of immune cells as described previously28. The study was approved by UCSD IRB. Rapid research autopsies were performed within 6 hours after PWH death, following established protocol28,29.

[0475] Table 2. Clinical demographics of “Last Gift” cohort

[0476] Age pVL CD4

[0477] ID Gender ART Clinical diagnoses of (copies / mL) counts

[0478] LG21 TF 72 <30 157 FTC / TAF+DTG Hepatic CA

[0479] Metastatic anal cancer,

[0480] LG29 M 48 <30 87 FTC / TAF / BIC

[0481] Kaposi Sarcoma

[0482] Esophageal,

[0483] LG33 M 64 <30 162 FTC / TAF+DTG

[0484] Hepatic CA

[0485] Disseminated

[0486] LG34 M 32 <30 45 FTC / TAF+DTG

[0487] multi drug resistant

[0488] TF, Transfeminine; M, male; F, female; pVL, plasma viral load; ART, antiretroviral therapy; FTC, emtricitabine; TAF, tenofovir alafenamide; DTG, dolutegravir; BIC, bictegravir; MAI, mycobacterium avium-intracellulare; ESRD, end-stage renal disease.

[0489] Example 3: Animal studies

[0490] Rhesus macaques (Macaco mulatto) were housed at the Oregon National Primate Research Center (ONPRC) or California National Primate Research Center (CNPRC) (Table 3). The care and use of non-human primates (NHPs) were approved and regulated by the individual Institutional Animal Care and Use Committee (IACUC). Both animal care facilities are accredited by the US Department of Agriculture and the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). NHPs from ONPRC were intravenously inoculated with 5,000 TCID50SIVmac239M and treated with ART (5.1 mg kg1d1tenofovir disoproxil, 40 mg kg1d1emtricitabine and 2.5 mg kg1d1dolutegravir in a solution containing 15% (v / v) kleptose at pH 4.2) beginning 9 days post-infection (dpi) for a >60 weeks before ART interruption >300 days prior to brain tissue collection. At the time of necropsy, these animals wereAttorney Docket No. 393976-00119

[0491] considered post-therapy controllers with SIV plasma viral loads (pVL) <600 copies / mL. NHPs from CNPRC were intravenously infected with 1,000 TCID50 of SIVmac251. ART (tenofovir, dolutegravir, and emtricitabine) started at week 6 post-infection and was maintained for 14 weeks prior to brain collection. At the time of necropsy, NHPs from CNPRC had SIV pVL <400 copies / mL. Brain tissues from both centers were collected after necropsy and shipped to the UNC HIV Cure Center via overnight special delivery in media with antibiotics and ART. CNS cells were then immediately isolated from these tissues for latency reversal studies.

[0492] Table 3. Characterization of the NHP

[0493] CNPRC, California National Primate Research Center; ONPRC, Oregon National Primate

[0494] A• 1 m r.A1 pVL CD4 counts

[0495] Sources Animal ID Gender Ag

[0496] ae (yr), ■,

[0497] ' (copies / ml, „,

[0498] L) (cells / p1

[0499] L)

[0500] CNPRC NHP 1 F 10 400 288

[0501] CNPRC NHP 2 M 6 40 275

[0502] CNPRC NHP 3 F 6 290 487

[0503] ONPRC NHP 4 M 18 600 403

[0504] ONPRC NHP 5 F 6 72 506

[0505] ONPRC NHP 6 M 8 25 342

[0506] Research Center; NHP, non-human primate; M, male; F, female; pVL, plasma viral load.

[0507] Example 4: HIV infection in primary CD4+T cells

[0508] A primary CD4+T cell infection model was established using cells from donors without HIV (obtained from UCLA CFAR). Briefly, CD4+T cells were activated with anti-CD3 / CD28 dynabeads (Gibco) in RPMI RIO medium supplemented with 100 U / mL IL-2 for two days. Ten million activated cells were then infected with HIV-1 SF162 by centrifugation at 1200 g for 2 hours at 37°C. Following centrifugation, cells were plated and treated with or without 40 μM NaCr in RPMI R10 supplemented with 40 U / mL IL -2. One day later, the virus was washed off, the medium was replaced, and NaCr was re-supplemented. Cells were harvested for RT-qPCRAttorney Docket No. 393976-00119

[0509] targeting the HIV LTR at 1-, 4-, 6-, and 8-days post-infection. And p24 ELISA was performed in the supernatants 8 days post-infection.

[0510] Example 5: HIV latency models

[0511] 2D10 cell model of HIV latency, which carries a lentiviral vector that expresses Tat with H13L mutation and Rev in cis, along with a destabilized green fluorescent protein (d2EGFP) replacing Nef30, was used in this model. 2D10 cells were cultured in RPMI R10 in a 37°C incubator with 5% CO2. A primary CD4+T cell model of latency was also used, as previously described31’33. Briefly, CD4+T cells obtained from HIV seronegative individuals were infected with pNL4.3 6-GFP. GFP-positive cells were sorted and subsequently co-cultured with H80 feeder cells to facilitate the establishment of HIV latency. Finally, latently infected GFP-negative CD4+T cells were sorted and maintained as the primary CD4+T cell model of HIV latency. To reactivate the primary CD4+T cell model of HIV latency, cells were stimulated with anti-CD3 / CD28 dynabeads in RPMI R10 medium supplemented with 100 U / mL IL-2. After 48 hours of activation, dynabeads were removed, and the media was replaced every 2-3 days with fresh RPMI R10 containing 40 U / mL IL-2, maintaining a cell density of 106cells / mL. Viral gene expression was assessed by measuring GFP expression using flow cytometry.

[0512] Example 6: HIV gene expression by RT-qPCR analysis or flow cytometry

[0513] Total RNA was extracted from the cells using the RNeasy mini kit (Qiagen) and subsequently treated with DNase I (Invitrogen) to remove genomic DNA. First-strand cDNA was synthesized using Superscript III (Invitrogen) and random primers (Invitrogen). RT-qPCR (TaqMan, Applied Biosystems Inc.) was conducted on an ABI QuantStudio 5 system using primers and probe sets targeting the long LTR or gag region of HIV. The SDHA primers / probe set (Applied Biosystems Inc.) served as an internal control. HIV transcription was also quantified through GFP expression measured by flow cytometry, with data analyzed using FlowJo Software (version XI 0.9.0). Cell viability was assessed during flow cytometry using Live / Dead dye (Invitrogen).

[0514] Example 7: HIV p24 flow cytometry assay

[0515] Following NaCr treatment, the frequency of p24-producing cells was quantified via intracellular p24 staining using the KC57-FITC antibody (Beckman Colter), as previously

[0516] Attorney Docket No. 393976-00119

[0517] described34Briefly, cells were fixed and permeabilized with Cytofix / Cytoperm solution (BD Biosciences) for 20 minutes at 4°C. After fixation, cells were washed with Perm / W ash Buffer (BD Biosciences) and stained with a 1:40 dilution of the anti-p24 KC57-FITC antibody in 100 pL Perm / Wash Buffer for 30 minutes at 4°C. Following wash with Perm / Wash Buffer, stained cells were analyzed by flow cytometry.

[0518] Example 8: Luciferase assay

[0519] TZM-bl luciferase reporter cells were obtained from the NIH HIV Reagent Repository and cultured in DMEM D10 (10% FBS; 1% Penicillin Streptomycin; 10 mM HEPES; 2 mM L-Glutamine; 1 mM Sodium Pyruvate). Cells were seeded in a black 96-well plate and incubated overnight to allow cell attachment. The following day, the cells were transfected with 0.03 pg of pcDNA3.1 empty vector (EV), Tat, or HDAC3 wildtype (WT) HDAC3, mutated HDAC3 (HDAC3-VRPP or HDAC3-Y298H), or Tat in combination with WT or mutated HDAC3 using Lipofectamine™ 3000 Transfection Reagent (Invitrogen). After 48 hours, Tat-driven HIV transactivation was measured using a luciferase assay (Promega). Briefly, cells were washed with PBS and lysed with 20 pL of Reporter Lysis Buffer. The lysates were then mixed with 100 pL of Luciferase Assay Reagent, and the luminescence was measured. The results were normalized to the EV control.

[0520] Example 9: Western Blot

[0521] Total cell protein was extracted using RIPA lysis buffer (Sigma-Aldrich) containing a lx protease and phosphatase inhibitor cocktail (Cell Signaling). Protein expression was assessed using the following antibodies: anti-NF-KB2 pl00 / p52 (Cell Signaling), anti-ENL (Cell Signaling), anti-CDYL (Gene Tex), and anti-P-Actin (Cell Signaling). For histone proteins, compounds (see the Key Resources Table) were added to culture media for the indicated periods, and total histones were extracted from the cells using the EpiQuik Total Histone Extraction Kit (EpigenTek). Histone modifications were analyzed using the following antibodies: histone H3 lysine 18 crotonylation (H3K18Cr, PTM-Bio), histone H3 lysine 27 crotonylation (H3K27Cr, PTM-Bio), anti-panKac (i.e. anti-histone H3 acetyl K9 + K14 + K18 + K23 + K27, Abeam), anti-panLactyllysine (PTM-Bio), anti-panButyryllysine (PTM-Bio), anti-panPropionyllysine (PTM-Bio), and anti-total histone 3 (Cell Signaling).

[0522] Attorney Docket No. 393976-00119

[0523] Example 10: Molecular docking of HDACi against the crystal structure of HDAC3

[0524] AlphaFold (from CollabFold) was utilized to predict the effect of the removal of the various co-repressors deacetyl ase-activating domain (DAD) and inositol tetraphosphate (IP4), found in the protein structure (Protein Data Bank [PDB]: 4A69), from HDAC3. After structural alignment between the crystal structure and the predicted sequence, the inventors validated that the crystal structure could be used for molecular docking. The HDAC3 crystal structure (PDB: 4A69) was then modified as follows: the DAD co-repressor was removed, IP4, and acetate from the structure. The protein was prepared using the Protein Preparation Wizard in Maestro v13.3 (Schrodinger). LigPrep generated the molecular conformers and protonation states from the ligand SMILES strings. The box was centered on residue Y298 next to the Zn2+binding site. Molecular docking was then carried out using Schrodinger’s Glide SP (standard precision), generating up to 5 poses for each molecule. The top-scoring molecules are used in this analysis. The analysis and molecular visualization were carried out with ChimeraX (https: / / www.rbvi.ucsf.edu / chimerax).

[0525] Example 11: Virtual Screening of FDA-Approved Compounds

[0526] To investigate the docking behavior of selective HDCRi within the HDAC3 protein, the inventors first generated a high-confidence structural model ofHDAC3. The amino acid sequence of human HDAC3 (UniProt ID: 015379) was retrieved from the UniProt database. The three-dimensional structure was then predicted using the AF3 server35(https: / / alphafoldserver.com / ). The resulting model was evaluated for structural integrity and used as the receptor for subsequent virtual screening experiments. To identify potential HDCRi candidates, an in silico screening of 1101 FDA-approved compounds obtained from the PubChem database (https: / / pubchem.ncbi.nlm.nih.gov / ) was conducted. The molecular structures were downloaded in SMILES format and converted to PDBQT format using Open Babel (Obabel), ensuring compatibility with the docking software. Then, docking simulations were performed using AutoDock Vina, employing a search grid (dimensions: 54 * 54 x 54 A) centered at coordinates (32.11, -48.947, 33.303) to encompass the entire HDAC3 catalytic site. Default docking parameters were used, including the genetic algorithm (GA) with the following settings: Number of GA runs: 10; Population size: 150; Maximum number of evaluations: 2,500,000; Maximum number of generations: 27,000. Each compound was subjected to 20 docking poses to ensure aAttorney Docket No. 393976-00119

[0527] comprehensive sampling of potential binding interactions. The protein-ligand interaction profdes were visualized and analyzed using ChimeraX to assess binding orientations relative to the enzymatic zinc-binding pocket.

[0528] Example 12: Chromatin immunoprecipitation (ChIP) assays

[0529] ChIP assays were performed as previously described36with modifications. 2D 10 cells were treated with selective HDCRi or DMSO control for 24 hours. Five million cells were cross-linked with 1% formaldehyde (Sigma-Aldrich) by rotation for 10 minutes at room temperature. To quench cross-linking, 125 mM glycine was added and mixed by inversion. Cells were then washed with PBS (Gibco), and cell pellets were flash -frozen in liquid nitrogen and stored at -80°C. Nuclei were isolated by resuspending the cell pellet in 10 mL of rinse buffer #1 (50 mM HEPES-pH 8.0, 140 mMNaCl, 1 mM EDTA, 10% glycerol, 0.5% NP40, 0.25% Triton X 100), incubating on ice for 10 minutes, and centrifuging at 1200 g for 5 minutes at 4°C. The pellet was resuspended in 10 mL of rinse buffer #2 (10 mM Tris-pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 200 mM NaCl) and centrifuged again. To remove residual salts, 5 mL of shearing buffer (0.1% SDS, 1 mM EDTA, pH 8.0, 10 mM Tris-HCl, pH 8.0) was carefully added, and the sample was spun at 1200 g for 3 minutes at 4°C, with the wash step repeated. The isolated nuclei were resuspended in 90 pL of shearing buffer (with lx protease inhibitor) and transferred to glass microtubes (Covaris). Next, 10 pL of nanodroplet cavitation reagents (MegaShear, Triangle Biotechnology) were added to the microtubes. Samples were sonicated in a Covaris E110 instrument at 4 °C for 7.5 minutes. After sonication, the chromatin was immunoprecipitated using antibodies against normal rabbit IgG (Cell Signaling), H3K18Cr, H3K27Cr, and panKac. Co-immunoprecipitated DNA was recovered using the ChIP Clean & Concentration kit (Zymo Research) and analyzed by SYBR Green qPCR (Applied Biosystems Inc.) with primers targeting the HIV long LTR and Nucl regions. Data were presented relative to the input control.

[0530] Example 13: Isolation and culturing of brain microglia from PWH and NHPs

[0531] The inventors isolated the brain MG from PWH and NHPs following their published protocol28. Briefly, fresh brain tissue was mechanically dissociated in lx HBSS (Gibco) containing DNase I. The released cells were transferred to a 50 mL conical tube. Myelin debris was removed using a 35% Percoll density gradient37to generate a single-cell suspension of CNS cells. TheAttorney Docket No. 393976-00119

[0532] isolated cells were resuspended in 5 mL of ACK lysis buffer (Gibco) and incubated at 37°C for 10 minutes to remove red blood cells. After centrifugation, immune cells were then depleted from the other CNS cell population using CD3+T cell selection. For human samples, the EasySep Release Human CD3 Positive Selection Kit (STEMCELL Technologies) was used. For NHP samples, the CD3 MicroBead Kit, nonhuman primate (Miltenyi Biotec) was applied. Finally, brain MG were purified from the CD3-depleted CNS cell population. For human samples, CDllb MicroBeads, human and mouse (Miltenyi Biotec) were utilized, while for NHP samples, CD1 lb MicroBeads, NHP (Miltenyi Biotec) were used. Purified brain MG were cultured in DMEM / F12 supplemented with human or NHP M-CSF for 1-2 weeks before treatment with LRAs for latency reversal. Brain MG were treated with LRAs or DMSO control. After 24 hours, the drugs were removed, and the cells were cultured for another 6 days. Culture supernatants were harvested for HIV RNA or SIV RNA measurement by RT-droplet digital PCR.

[0533] Example 14: Cell-associated and cell-free HIV or SIV RNA quantified by droplet digital PCR (ddPCR)

[0534] Viral RNA was extracted from PWH-derived rCD4+T cells and brain MG using RNAeasy Mini kit (Qiagen) while cell-free RNA was isolated from culture supernatants with QIAamp viral RNA mini kit (Qiagen). Total RNA was then treated with DNase I to remove genomic DNA, and cDNA was synthesized using the SuperScript IV First-Strand Synthesis System (Invitrogen). HIV RNA was quantified by RT-ddPCR using two sets of primers / probes targeting HIV gag or long-LTR regions, while SIV RNA was quantified using two sets of primers / probes targeting the gag region. PCR cycling conditions were as follows: 95°C for 10 minutes, followed by 45 cycles of 30 seconds at 94°C, 60 seconds at 57°C, and a final droplet cure step at 98°C for 10 minutes. Droplets were analyzed using QuantaSoft in absolute quantification mode.

[0535] Statistical analysis

[0536] Statistical analyses were performed with GraphPad Prism 10 software. In all graphs, the error bars represent the standard deviation and are only shown for experiments with n = 3 or greater, as indicated. Comparisons between control and sample datapoints were made using either a two-tailed unpaired Student’s / -test or two-way analysis of variance (ANOVA) with multiple-

[0537] Attorney Docket No. 393976-00119

[0538] comparison analyses, or other statistical methods as specified in the figure legends, with the confidence limit for significance set at 0.05 or less.

[0539] Example 15: In vitro decrotonylase / deacetylase activity assay

[0540] The decrotonylase and acetylase activity assays were performed following an established protocol (see R. Fellows, P. Varga-Weisz, In vitro Enzymatic Assays of Histone Decrotonylation on Recombinant Histones. BioProtoc 8, (2018)). Briefly, 100 pM crotonyl-CoA (Sigma- Aldrich) or acetyl-CoA (Roche) and histone H3 (Active motif) were incubated with the p300 catalytic domain (Enzo Life Science) for 2 h at 30°C in a thermocycler. Reactions were terminated by heating at 65°C for 5 min. The resulting crotonylated or acetylated histone substrates were then aliquoted into PCR tubes. To assess the effect of citarinostat on decrotonylase or deacetylase activity, the histone substrates were treated with HDAC3 / NCOR1 (Enzo Life Science), HDAC2 (Abeam), or HDAC8 (Active motif), in the presence or absence of the inhibitor citarinostat. The reactions were incubated for 2 hours at 30°C in a thermocycler. Control reactions were included: a blank (no HDAC or inhibitor) and an enzyme control (HDAC added without inhibitor). Following incubation, NuPAGE™ LDS Sample Buffer (4X) (Invitrogen) was added to each reaction, followed by a 5-minute incubation at 95°C. Samples were then subjected to Western blot analysis. Histone modifications were detected using antibodies specific to H3K18Cr, H3K27Cr, panKac, and total histone H3.

[0541] Example 16: Molecular Docking of Citarinostat and SAHA against HDAC proteins

[0542] Structural models of human HDAC1, HDAC2, HDAC 3, and HDAC 8 were generated using AlphaFold3 (see J. Jumper, R. Evans, A. Pritzel, T. Green, M. Figumov, O. Ronneberger, K. Tunyasuvunakool, R. Bates, A. Zidek, A. Potapenko, A. Bridgland, C. Meyer, S. A. A. Kohl, A. J. Ballard, A. Cowie, B. Romera-Paredes, S. Nikolov, R. Jain, J. Adler, T. Back, S. Petersen, D. Reiman, E. Clancy, M. Zielinski, M. Steinegger, M. Pacholska, T. Berghammer, S. Bodenstein, D. Silver, O. Vinyals, A. W. Senior, K. Kavukcuoglu, P. Kohli, D. Hassabis, Highly accurate protein structure prediction with AlphaFold. Nature 596, 583-589 (2021);. J. A.-O. Abramson, J. A.-O. Adler, J. Dunger, R. A.-O. Evans, T. A.-O. Green, A. A.-O. Pritzel, O. A.-O. Ronneberger, L. A.-O. Willmore, A. A.-O. Ballard, J. A.-O. Bambrick, S. W. Bodenstein, D. A. Evans, C. A.-O. Hung, M. O'Neill, D. A.-O. Reiman, K. A.-O. Tunyasuvunakool, Z. A.-O. Wu, A. Zemgulyte,

[0543] Attorney Docket No. 393976-00119

[0544] E. Arvaniti, C. A.-O. X. Beattie, O. A.-O. Bertolli, A. Bridgland, A. A.-O. Cherepanov, M. Congreve, A. I. Cowen-Rivers, A. A.-O. Cowie, M. A.-O. Figumov, F. B. Fuchs, H. Gladman, R. Jain, Y. A.-O. Khan, C. M. R. Low, K. Perlin, A. Potapenko, P. Savy, S. Singh, A. A.-O. Stecula, A. Thillaisundaram, C. A.-O. Tong, S. A.-O. Yakneen, E. A.-O. Zhong, M. Zielinski, A. A.-O. Zidek, V. Bapst, P. A.-O. Kohli, M. A.-O. Jaderberg, D. A.-O. Hassabis, J. A.-O. Jumper, Accurate structure prediction of biomolecular interactions with AlphaFold 3) and subsequently were prepared for docking by adding polar hydrogens. Partial charges were assigned, and proteins were converted to the PDBQT format using AutoDockTools. Ligand structures for SAHA and citarinostat were generated from SMILES strings, energy-minimized, and prepared with appropriate protonation states prior to docking. Molecular docking was performed using AutoDock Vina (see O. Trott, A. J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading), which employs an efficient stochastic global search algorithm coupled with an empirical scoring function. Docking grids were centered on the conserved catalytic region adjacent to the zinc-binding site, encompassing the canonical HDAC active-site tunnel as well as the surrounding cap and outer pocket regions. Grid dimensions were selected to allow sufficient conformational sampling of both pocket-bound and extended binding modes. For each ligand-protein pair, multiple binding poses were generated, and the top-ranked pose based on predicted binding affinity was selected for further analysis.

[0545] Protein-ligand interactions were analyzed using LigPlot+ (see R. A. Laskowski, M. B. Swindells, LigPlot+: multiple ligand-protein interaction diagrams for drug discovery), which provides two-dimensional schematic representations of hydrogen bonds and hydrophobic contacts. These interaction maps were used to identify conserved and isoform-specific residues involved in ligand recognition across HDAC1 / 2 / 3 / 8. Three-dimensional visualization and structural inspection were carried out using UCSF ChimeraX (see E. F. Pettersen, T. D. Goddard, C. C. Huang, E. C. Meng, G. S. Couch, T. I. Croll, J. A.-O. Morris, T. A.-O. Ferrin, UCSF ChimeraX: Structure visualization for researchers, educators, and developers).

[0546] Example 17: CRISPR-Cas9 gene knockout

[0547] Protospacer sequences targeting HDAC 3 and a non-targeting control were designed by Integrated DNA Technologies (IDT). CRISPR-Cas9 ribonucleoprotein (RNP) complexes were

[0548] Attorney Docket No. 393976-00119

[0549] assembled by annealing crRNA and tracrRNA (IDT) at a 1:1 molar ratio (final concentration 100 pM) in duplex buffer (IDT) with heating to 95°C followed by gradual cooling to 25°C. Fresh RNP complexes were prepared for each nucleofection by incubating 49.6 pmol of Alt-R S.p. Cas9 nuclease (62 pM; IDT) with 100 pmol of the annealed guide RNA duplex and 0.8 pL of poly-L-glutamic acid (15 kDa, 100 mg / mL; Alamanda Polymers). For nucleofection, 2D10 cells were pelleted (90 x gfor 10 min), washed with PBS, and resuspended in SE Cell Line Nucleofector Solution (Lonza) at 1x106cells per 20 pL. The cell suspension was combined with the RNP complex and transfected using a 4D-Nucleofector device (Lonza) with the CL-120 program. Cells were immediately resuspended in pre-warmed R10 medium and cultured at 37°C. Five days post-nucleofection, cells were treated for 30 minutes with DMSO (vehicle), 350 nM SAHA, 0.1 pM citarinostat, 5 pM RGFP966, or 5 pM mod-RGFP966. Histones were then extracted and analyzed by western blot for specific post-translational modifications (PTMs) and total histone H3.

[0550] Example 18: Plasmid transfection by nucleofection

[0551] A plasmid encoding wild-type FLAG-tagged HDAC3 was obtained from Addgene, and site-directed mutants (D57A, Q113A, R265A, R301A) were generated by GenScript. For nucleofection, 2D10 cells were pelleted (90 x g for 10 min), washed with PBS, and resuspended in SE Cell Line Nucleofector Solution at a density of 2 x 106cells per 100 pL. Cells were transfected with 1 pg of either empty vector control or HDAC3 plasmid using a 4D-Nucleofector device (Lonza) with program CK-116. Following transfection, cells were immediately resuspended in pre-warmed RPMI R10 medium and cultured at 37°C. Histones were extracted 5-7 days post-transfection and analyzed by western blot for relevant histone PTMs and total histone H3.

[0552] REFERENCES

[0553] 1 Margolis, D. M. How Might We Cure HIV? Curr Infect Dis Rep 16, 392, doi:10.1007 / s11908-014-0392-2 (2014).

[0554] 2 Bruner, K. M., Hosmane, N. N. & Siliciano, R. F. Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol 23, 192-203, doi:10.1016 / j.tim.2015.01.013 (2015).

[0555] 3 Siliciano, J. D. et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV- 1 in resting CD4+ T cells. Nat Med 9, 727-728, doi:10.1038 / nm880 (2003).

[0556] 4 Margolis, D. M. et al. Curing HIV: Seeking to Target and Clear Persistent Infection. Cell 181, 189-206, doi:https: / / doi.org / 10.1016 / j. cell.2020.03, 005 (2020).

[0557] Attorney Docket No. 393976-00119

[0558] 5 Cohn, L B., Chomont, N. & Deeks, S. G. The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies. Cell Host & Microbe 27, 519-530,

[0559] doi: https: / / doi. org / 10,1016 / j, chom,2020, 03.014 (2020).

[0560] 6 Ho, Y. C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540-551, doi:10.1016 / j.cell.2013.09.020 (2013).

[0561] 7 Siliciano, J. D. & Siliciano, R. F. Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure. J Infect Dis 223, 13-21, doi:10.1093 / infdis / jiaa649 (2021).

[0562] 8 Chun, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America 94, 13193-13197, doi:10.1073 / pnas.94.24.13193 (1997).

[0563] 9 Hakre, S., Chavez, L., Shirakawa, K. & Verdin, E. Epigenetic regulation of HIV latency.

[0564] Current Opinion in HIV and AIDS 6 (2011).

[0565] 10 Nguyen, K. & Karn, J. The sounds of silencing: dynamic epigenetic control of HIV latency. Curr Opin HIV AIDS 19, 102-109, doi:10.1097 / COH.0000000000000850 (2024).

[0566] 11 Blazkova, J. et al. Paucity of HIV DNA methylation in latently infected, resting CD4+ T cells from infected individuals receiving antiretroviral therapy. J Virol 86, 5390-5392, doi:10.1128 / JVI.00040-12 (2012).

[0567] 12 Jiang, G., Espeseth, A., Hazuda Daria, J. & Margolis David, M. c-Myc and Spl Contribute to Proviral Latency by Recruiting Histone Deacetylase 1 to the Human Immunodeficiency Virus Type 1 Promoter. Journal of Virology 81, 10914-10923, doi: 10.1128 / jvi.01208-07 (2007).

[0568] 13 Friedman, J. et al. Epigenetic Silencing of HIV-1 by the Histone H3 Lysine 27 Methyltransferase Enhancer of Zeste 2. Journal of Virology 85, 9078-9089,

[0569] doi: 10.1128 / jvi.00836-11 (2011).

[0570] 14 Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485, doi:10.1038 / nature11286 (2012).

[0571] 15 Sogaard, O. S. et al. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.

[0572] PLoS Pathog 11, el005142, doi:10.1371 / journal.ppat,1005142 (2015).

[0573] 16 Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485, doi:10.1038 / nature11286 (2012).

[0574] 17 Rasmussen, T. A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1 / 2, single group, clinical trial. Lancet HIV el3-21, doi: 10.1016 / S2352-3018(14)70014-1 (2014).

[0575] 18 Sabari, B. R. et al. Intracellular crotonyl-CoA stimulates transcription through p300- catalyzed histone crotonylation. Mol Cell 58, 203-215, doi:10.1016 / j.molcel.2015.02.029 (2015).

[0576] 19 Gao, D. et al. P300 regulates histone crotonylation and preimplantation embryo development. Nat Commun 15, 6418, doi:10.1038 / s41467-024-50731-0 (2024).

[0577] 20 Chen, Y. et al. Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteomics 6, 812-819, doi: 10.1074 / mcp. M700021 - MCP200 (2007).

[0578] Attorney Docket No. 393976-00119

[0579] 21 Sabari, B. R., Zhang, D., Allis, C. D. & Zhao, Y. Metabolic regulation of gene expression through histone acylations. Nat Rev Mol Cell Biol 18, 90-101, doi:10.1038 / nrm.2016.140 (2017).

[0580] 22 Wei, W. et al. Class I histone deacetylases are major histone decrotonylases: evidence for critical and broad function of histone crotonylation in transcription. Cell Res 27, 898-915, doi:10.1038 / cr.2017.68 (2017).

[0581] 23 Kelly, R. D. W. et al. Histone deacetylase (HD AC) 1 and 2 complexes regulate both histone acetylation and crotonylation in vivo.

[0582] 24 Jiang, G. et al. HIV latency is reversed by ACSS2-driven histone crotonylation. J Clin Invest 128, 1190-1198, doi:10.1172 / JCI98071 (2018).

[0583] 25 Zhao, D. et al. YEATS2 is a selective histone crotonylation reader.

[0584] 26 Li, Y. et al. Molecular Coupling of Histone Crotonylation and Active Transcription by AF9 YEATS Domain.

[0585] 27 Andrews, F. H. et al. The Tafl4 YEATS domain is a reader of histone crotonylation.

[0586] 28 Tang, Y. et al. Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy. J Clin Invest 133, doi:10.1172 / JCI167417 (2023).

[0587] 29 Riggs, P. K. et al. Lessons for Understanding Central Nervous System HIV Reservoirs from the Last Gift Program. Curr HIV AIDS Rep 19, 566-579, doi: 10.1007 / s 11904-022- 00628-8 (2022).

[0588] 30 Pearson, R. et al. Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. J Virol 82, 12291-12303, doi:10.1128 / JVI.01383-08 (2008).

[0589] 31 Bradley, T., Ferrari, G., Haynes, B. F., Margolis, D. M. & Browne, E. P. Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. Cell Rep 25, 107-117 el03, doi:10.1016 / j.celrep.2018.09.020 (2018).

[0590] 32 Li, D. et al. Crotonylation sensitizes lAPi-induced disruption of latent HIV by enhancing plOO cleavage into p52. iScience 25, 103649, doi: 10.1016 / j.isci.2021.103649 (2022).

[0591] 33 Li, D. et al. Depletion of HIV reservoir by activation of ISR signaling in resting CD4(+)T cells. iScience 26, 105743, doi: 10.1016 / j.isci.2022.105743 (2023).

[0592] 34 Bosque, A. & Planelles, V. Induction of HIV- 1 latency and reactivation in primary memory CD4+ T cells.

[0593] 35 Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493-500, doi:10.1038 / s41586-024-07487-w (2024).

[0594] 36 Chiarella, A. M. et al. Cavitation Enhancement Increases the Efficiency and Consistency of Chromatin Fragmentation from Fixed Cells for Downstream Quantitative Applications. Biochemistry 57, 2756-2761, doi: 10.1021 / acs.biochem.8b00075 (2018).

[0595] 37 Grabert, K. & McColl, B. W. in Macrophages: Methods and Protocols (ed Germain Roussel et) 77-86 (Springer New York, 2018).

[0596] 38 Li, Y. et al. Molecular Coupling of Histone Crotonylation and Active Transcription by AF9 YEATS Domain. Molecular Cell 62, 181-193,

[0597] doi: https: / / doi.org / 10,1016 / j,molcel.2016,03,028 (2016).

[0598] 39 Kwapis, J. L. et al. Context and Auditory Fear are Differentially Regulated by HDAC3 Activity in the Lateral and Basal Subnuclei of the Amygdala. Neuropsychopharmacology 42, 1284-1294, doi:10.1038 / npp.2016.274 (2017).

[0599] Attorney Docket No. 393976-00119

[0600] 40 Liu, X. et al. MOF as an evolutionarily conserved histone crotonyltransferase and transcriptional activation by histone acetyltransferase-deficient and crotonyltransferase- competent CBP / p300. Cell Discov3, 17016, doi:10.1038 / celldisc.2017.16 (2017).

[0601] 41 Wu, Q. et al. Ultradeep Lysine Crotonylome Reveals the Crotonylation Enhancement on Both Histones and Nonhistone Proteins by SAHA Treatment. Journal of Proteome Research 16, 3664-3671, doi:10.1021 / acs.jproteome.7b00380 (2017).

[0602] 42 Zhang, L., Zhang, J., Jiang, Q., Zhang, L. & Song, W. Zinc binding groups for histone deacetylase inhibitors. J Enzyme Inhib Med Chem 33, 714-721,

[0603] doi: 10.1080 / 14756366.2017.1417274 (2018).

[0604] 43 Manal, M., Chandrasekar, M. J., Gomathi Priya, J. & Nanjan, M. J. Inhibitors of histone deacetylase as antitumor agents: A critical review. Bioorg Chem 67, 18-42, doi:10.1016 / j.bioorg.2016.05.005 (2016).

[0605] 44 Zhang, X. D., Gillespie, S. K., Borrow, J. M. & Hersey, P The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 3, 425-435 (2004).

[0606] 45 Knoche, S. M. et al. The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer. PLoS One 17, e0273518, doi:10.1371 / journal.pone.0273518 (2022).

[0607] 46 Shirakawa, K., Chavez, L., Hakre, S., Calvanese, V. & Verdin, E. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 21, 277-285, doi:10.1016 / j.tim.2013.02.005 (2013).

[0608] 47 Lin, S., Zhang, Y, Ying, H. & Zhu, H. HIV-1 reactivation induced by apicidin involves histone modification in latently infected cells. Curr HIV Res 9, 202-208, doi:10.2174 / 157016211796320333 (2011).

[0609] 48 Narasipura, S. D., Kim, S. & Al-Harthi, L. Epigenetic regulation of HIV-1 latency in astrocytes. J Virol 88, 3031-3038, doi:10.1128 / JVI.03333-13 (2014).

[0610] 49 Ndukwe, K., Serrano, P. A., Rockwell, P, Xie, L. & Figueiredo-Pereira, M. E. Brainpenetrant histone deacetylase inhibitor RG2833 improves spatial memory in females of an Alzheimer's disease rat model. J Alzheimers Dis 104, 173-190,

[0611] doi: 10.1177 / 13872877251314777 (2025).

[0612] 50 Leus, N. G. et al. HD AC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-kappaB p65 transcriptional activity. Biochem Pharmacol 108, 58-74, doi: 10.1016 / j.bcp.2016.03.010 (2016).

[0613] 51 Liu, J. et al. A Class I HD AC Inhibitor BG45 Alleviates Cognitive Impairment through the CaMKII / ITPK A / Ca(2+) Signaling Pathway. Pharmaceuticals (Basel) 15,

[0614] doi: 10.3390 / ph 15121481 (2022).

[0615] 52 Shabir, G. et al. Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016-2022). Pharmaceuticals (Basel) 16, doi: 10.3390 / ph 16081162 (2023).

[0616] 53 Han, S. & Lu, Y. Fluorine in anti -HIV drugs approved by FDA from 1981 to 2023. Eur J Med Chem 258, 115586, doi:10.1016 / j.ejmech.2023.115586 (2023).

[0617] 54 Arrar, M., Turnham, R., Pierce, L., de Oliveira, C. A. & McCammon, J. A. Structural insight into the separate roles of inositol tetraphosphate and deacetylase-activating domain in activation of histone deacetylase 3. Protein Sci 22, 83-92, doi:10.1002 / pro.2190 (2013).

[0618] Attorney Docket No. 393976-00119

[0619] 55 Li, J. H. et al. The histone deacetylase inhibitor chidamide induces intermittent viraemia in HIV-infected patients on suppressive antiretroviral therapy. HIV Med 21, 747-757, doi: 10.1111 / hiv.13027 (2020).

[0620] 56 Awad, M. M. et al. Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase lb Study. Front Oncol 11, 696512, doi:10.3389 / fonc.2021.696512 (2021).

[0621] 57 Yang, Q. et al. Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein. Signal Transduct Target Ther 9, 144, doi:10.1038 / s41392-024-01858-5 (2024).

[0622] 58 Ali, E. A., Jain, M., Pokhrel, A., Mooppan, U. & Wang, J. C. Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report. Leak Res Rep 22, 100473, doi: 10.1016 / j.lrr.2024.100473 (2024).

[0623] 59 Costagliola, D. G. et al. Dose of desferrioxamine and evolution of HIV-1 infection in thalassaemic patients. Br J Haematol 87, 849-852, doi: 10.1111 / j.1365- 2141.1994.tb06750.x (1994).

[0624] 60 Bukhtiyarova, M. etal. Discovery of an Anion-Dependent Farnesyltransferase Inhibitor from a Phenotypic Screen. ACS Med Chem Lett 12, 99-106, doi:10.1021 / acsmedchemlett.0c00551 (2021).

[0625] 61 Ta, T. M. etal. Insights Into Persistent HIV-1 Infection and Functional Cure: Novel Capabilities and Strategies. Front Microbiol 13, 862270, doi:10.3389 / fmicb.2022.862270 (2022).

[0626] 62 Jiang, G. et al. Synergistic Reactivation of Latent HIV Expression by Ingenol-3- Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. PLOS Pathogens 11, el005066, doi:10.1371 / journal.ppat,1005066 (2015).

[0627] 63 Khanal, S., Schank, M., El Gazzar, M., Moorman, J. P. & Yao, Z. Q. HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies. Cells 10, doi:10.3390 / cellsl0020475 (2021).

[0628] 64 Keedy, K. S. et al. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol 83, 4749-4756,

[0629] doi: 10.1128 / JVI.02585-08 (2009).

[0630] 65 Wei, D. G. etal. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 10, el004071,

[0631] doi: 10.1371 / journal.ppat.1004071 (2014).

[0632] 66 Irimia, R. & Piccaluga, P. P. Histone Deacetylase Inhibitors for Peripheral T-Cell Lymphomas. Cancers (Basel) 16, doi:10.3390 / cancersl6193359 (2024).

[0633] 67 He, Y. et al. Sodium Crotonate Alleviates Diabetic Kidney Disease Partially Via the Histone Crotonylation Pathway. Inflammation 48, 254-275, doi:10.1007 / sl0753-024- 02047-w (2025).

[0634] 68 Martinez -Moreno, J. M. et al. Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease. IntJMol Sci 21, doi:10.3390 / ijms21114113 (2020).

[0635] 69 Lu, H. et al. Histone Deacetylase 3 Inhibition Decreases Cerebral Edema and Protects the Blood-Brain Barrier After Stroke. Mol Neurobiol 60, 235-246, doi:10.1007 / sl2035-022- 03083-z (2023).

[0636] Attorney Docket No. 393976-00119

[0637] 70 Bagal, V, Aggarwal, R., Vinod, P. K. & Priyakumar, U. D. MolGPT: Molecular Generation Using a Transformer-Decoder Model. J Chem Inf Model 62, 2064-2076, doi:10.1021 / acs.jcim.1c00600 (2022).

Claims

Attorney Docket No. 393976-001191. A method of reversing HIV latency in a subject diagnosed with an HIV infection, the method comprising administering a therapeutically effective amount of a compound of FormulaC-L-ZFormula (I)or any pharmaceutically acceptable salt and / or stereoisomer thereof, wherein:Z is selected from the group consisting ofL is a linker selected from the group consisting of a bond, -CH2-(CH2)n-, -CH=CH-,, wherein n is an integer selected from1-6; andAttorney Docket No. 393976-00119compound is a histone decrotonylation (HDCR) inhibitor.

2. The method of claim 1, wherein the HIV infection is an HIV-1 infection.

3. The method of claim 1 or 2, wherein the compound inhibits histone decrotonylation thereby triggering HIV transcription.

4. The method of claim 3, wherein triggering HIV transcription reactivates an HIV virus from its latent state to begin actively replicating thereby reversing HIV latency.

5. A method of inhibiting histone decrotonylation activity of a histone deacetylase 3 (HDAC3) enzyme, the method comprising contacting a cell with a compound of Formula (I):C-L-ZFormula (I)or any pharmaceutically acceptable salt and / or stereoisomer thereof, wherein:Attorney Docket No. 393976-00119L is a linker selected from the group consisting of a bond, -CH2-(CH2)n-, -CH=CH-,wherein the cell is obtained from an organism infected with HIV.

6. The method of claim 5, wherein the contacting step can occur in vivo or ex vivo.

7. The method of claim 5 or 6, wherein the organism is a mammal (e.g., human or non-human primate).

8. The method of any one of claims 5-7, wherein the cell is a T cell selected from the group consisting of CD4+ T cells, natural killer T (NKT) cells, Treg cells, and CD8+ cells.

9. The method of claim 8, wherein the cell is a primary CD4+ T cell.Attorney Docket No. 393976-0011910. The method of any one of claims 5-7, wherein the cell is a non-T cell selected from the group consisting of macrophages, dendritic cells, neutrophils, basophils, eosinophils, mast cells and microglia.

11. The method of claim 10, wherein the non-T cell is microglia from brain tissue.

12. The method of any one of the preceding claims, wherein the compound does not exhibit significant histone deacetylase (HD AC) activity.

13. The method of any one of the preceding claims, wherein the compound is an allosteric modulator of HDAC3.

14. The method of any one of the preceding claims, wherein the compound binds to HDAC3 outside of its zinc binding pocket.

15. The method of claim 14, wherein the compound binds to amino acid residues R265, R301, QI 13 and D57 located outside of the zinc binding pocket of HDAC3.

16. The method of any one of the preceding claims, wherein17. The method of claim 16, wherein L is selected from a group consisting of a bond, -CH2-Attorney Docket No. 393976-0011918. The method of claim 17, wherein C is selected from the group consisting of19. The method of claim 18, wherein the compound is selected from the group consisting ofAttorney Docket No. 393976-0011920. The method of any one of claim 1 -15, wherein Z is selected from the group consisting of21. The method of claim 20, wherein Z is 0 and C is selected from the group22. The method of claim 21, wherein L is -CH2(CH2)s-.Attorney Docket No. 393976-0011925. The method of claim 24, wherein the compound is26. A compound of Formula (I)C-L-ZFormula (I)or any pharmaceutically acceptable salt thereof, wherein: